

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:20:47 ON 03 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 3 Feb 2006 VOL 144 ISS 7  
FILE LAST UPDATED: 2 Feb 2006 (20060202/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

$$\begin{aligned} &= \gamma \\ &= \gamma \end{aligned}$$

=> d stat que  
L5 STR



```

VAR G1=CH/11
VAR G2=ME/14/17/X/CN/NH2
VAR G3=CH/19
VAR G4=CH3/OH/17/SH/23/26/N/X/CN
VAR G5=66/32/33/34
VAR G20=O/S/N/26/X/CN/AK/CY
NODE ATTRIBUTES:
NSPEC   IS RC      AT   34
DEFAULT MLEVEL IS ATOM

```

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 33

STEREO ATTRIBUTES: NONE

L7 533 SEA FILE=REGISTRY SSS FUL L5  
L8 350 SEA FILE=REGISTRY ABB=ON PLU=ON P38/BI  
L9 128 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND KINASE  
L10 47 SEA FILE=REGISTRY ABB=ON PLU=ON (MITOGEN(W)ACTIVATED OR  
MAP) (L) KINASE (L) (P38 OR P(W)38)  
L11 18 SEA FILE=HCAPLUS ABB=ON PLU=ON L7  
L12 32869 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 OR L10 OR P38 OR P(W)38 OR  
MAP(2A) KINASE OR MITOGEN(W)ACTIVATED  
L13 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND L12  
L14 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND (PAIN OR ?ACHE? OR  
?EDEM? OR ?ANALGES? OR ?FEVER? OR ?IMMUNE? OR HIV? OR HTLV OR  
?CANCER? OR ?NEOPLAS? OR ?MALIG? OR ?TUMOR? OR ?PROLIVER? OR  
?ANGIOGEN? OR ?NEURODE? OR ?VIRAL? OR ?INFLAM? OR ?ASTHM? OR  
?DIABET? OR (BLOOD OR BLD) (W) SUGAR OR BOWEL(W) DISEASE)  
L15 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND (?PULMON? OR ?OSTEOPOR  
? OR BONE(W) LOSS OR ?DEMENT? OR ?SENIL? OR ?ALZHEM? OR ?PSORI?  
OR ?ARTHRI? OR ?GOUT?)  
L16 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15)

=>

=>

=> d ibib abs hitstr l16 1-4

L16 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:160831 HCAPLUS

DOCUMENT NUMBER: 142:261564

TITLE: Heteroaryl-substituted pyrrolo-triazine compounds  
useful as kinase inhibitors, particularly p38  
kinases, and their preparation, pharmaceutical  
compositions, and use

INVENTOR(S): Leftheris, Katerina; Wroblewski, Stephen T.; Dyckman,  
Alaric J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S.  
Ser. No. 420,399.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043306	A1	20050224	US 2003-678388	20031003
US 2004082582	A1	20040429	US 2003-420399	20030422
WO 2005037838	A1	20050428	WO 2004-US30829	20040921

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-374938P P 20020423  
 US 2003-420399 A2 20030422  
 US 2003-678388 A 20031003

OTHER SOURCE(S): MARPAT 142:261564  
 GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I and their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, and solvates, are surprisingly advantageous as p38 kinase inhibitors [wherein X = O, OCO, S, halo, CN, absent, etc.; Z = (un)substituted heteroaryl; R1, R5 = independently H, alkyl, substituted alkyl, etc.; R2 = H, alkyl; R3 = H, Me, CF3, OMe, halo, CN, NH2, NH(Me); R4 = (un)substituted alk(en/yn)yl, heterocyclyl, hetero/aryl, etc.; R6 = at each occurrence independently halo, CF3, OCF3, CN, (un)substituted alkyl, sulfonamido, etc.; m = 0-3]. Compds. I have shown activity as inhibitors of p38.alpha./beta enzymes and TNF- $\alpha$ . For instance, II was prepared in 7 steps by (a) acylation of 4-methyl-3-nitrobenzoyl chloride with tert-Bu carbazate; (b) Boc-deprotection; (c) cyclization of the acyl hydrazide with MeC(OEt)<sub>3</sub>, (d) hydrogenation of the nitro intermediate over Pd/C; (e) coupling of the amine with chloride III (preparation given), (f) saponification of the ester; and (g) reaction with n-PrNH<sub>2</sub>.

IT 845884-78-8P 845884-79-9P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of heteroaryl pyrrolotriazine compds. as p38 kinase inhibitors)

RN 845884-78-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-(1H-1,2,4-triazol-3-yl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 845884-79-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-(1H-

Pryor 10\_696178

1,2,4-triazol-3-yl)phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 845884-68-6P 845884-71-1P 845884-72-2P  
845884-73-3P 845884-74-4P 845884-75-5P  
845884-84-6P 845884-85-7P 845884-86-8P  
845884-87-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteroaryl pyrrolotriazine compds. as p38 kinase inhibitors)

RN 845884-68-6 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 845884-71-1 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]amino]- (9CI) (CA INDEX NAME)





RN 845884-72-2 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-N-(1-methylethyl)-4-  
[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]amino]- (9CI) (CA  
INDEX NAME)



RN 845884-73-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(5S)-4,5-dihydro-5-  
methyl-1,3,4-oxadiazol-2-yl]-2-methylphenyl]amino]-5-methyl-N-(1-  
methylenepropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845884-74-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(5S)-4,5-dihydro-5-  
methyl-1,3,4-oxadiazol-2-yl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-  
methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 845884-75-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(1-ethylpropyl)-5-methyl-4-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 845884-84-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 845884-85-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 845884-86-8 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845884-87-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



IT 165245-96-5 179800-23-8

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; preparation of heteroaryl pyrrolotriazine compds. as  
p38 kinase inhibitors)

RN 165245-96-5 HCAPLUS

CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 179800-23-8 HCAPLUS

CN Kinase (phosphorylating), protein p38 $\beta$  (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


IT 845884-69-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(intermediate; preparation of heteroaryl pyrrolotriazine compds. as  
p38 kinase inhibitors)

RN 845884-69-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 845884-88-0, 4-(5-Cyano-2-methylphenylamino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heteroaryl pyrrolotriazine compds. as p38 kinase inhibitors)

RN 845884-88-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(5-cyano-2-methylphenyl)amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:875265 HCAPLUS

DOCUMENT NUMBER: 139:364963

TITLE: Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors, particularly p38 kinases, and their preparation, pharmaceutical compositions, and use

INVENTOR(S): Dyckman, Alaric; Leftheris, Katerina; Hynes, John

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091229	A1	20031106	WO 2003-US12420	20030418
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1503996	A1	20050209	EP 2003-718493	20030418
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005529890	T2	20051006	JP 2003-587789	20030418
US 2003232831	A1	20031218	US 2003-420445	20030422
NO 2004004592	A	20041119	NO 2004-4592	20041025
PRIORITY APPLN. INFO.:			US 2002-374907P	P 20020423
			WO 2003-US12420	W 20030418
OTHER SOURCE(S):	MARPAT 139:364963			
GI				




- AB Title compds. I and their pharmaceutically acceptable salts, prodrugs, and solvates, are surprisingly advantageous as **p38** kinase inhibitors [wherein: A = (un)substituted Ph; W = (un)substituted azine, 1,2-, 1,3-, or 1,4-diazine, or 1,2,4-triazine ring; R<sup>1</sup>, R<sup>4</sup> = H, (un)substituted alkyl, OH or derivs., SH or derivs., CO<sub>2</sub>H or derivs., NH<sub>2</sub> or derivs., halo, NO<sub>2</sub>, cyano; R<sup>2</sup> = H, alkyl; R<sup>3</sup> = H, Me, CF<sub>3</sub>, MeO, halo, cyano, NH<sub>2</sub>, or NHMe, preferably Me]. Seventeen specific compds. I and various intermediates were prepared. Compds. I selectively inhibited human **p38** α/β isoenzymes in vitro with IC<sub>50</sub> values below 500 nM. For instance, the pyrrolo[2,1-f][1,2,4]triazinone ester II underwent reduction of the ester to an alc. with LAH (86%), reoxidn. to an aldehyde with Jones reagent (65%), Grignard reaction of the aldehyde with PhMgBr and reoxidn. of the resultant alc. with Jones reagent (66% combined), chlorination of the ring oxo group with POCl<sub>3</sub> (100%), and aminolysis of the chloride with 3-amino-4-methylbenzoic acid (88%), to give title compound III.
- IT 621685-40-3P 621685-41-4P 621685-42-5P  
621685-44-7P 621685-45-8P 621685-46-9P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of aryl ketone pyrrolo[2,1-f][1,2,4]triazine compds. as **p38** kinase inhibitors)
- RN 621685-40-3 HCAPLUS
- CN Carbamic acid, [3-[(6-benzoyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-4-methylphenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 621685-41-4 HCAPLUS

CN Benzamide, 3-[(6-benzoyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-N-(2-methoxyethyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 621685-42-5 HCAPLUS

CN Benzamide, 3-[(6-benzoyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 621685-44-7 HCAPLUS

CN Methanone, [4-[(5-ethyl-2-methylphenyl)amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]phenyl- (9CI) (CA INDEX NAME)




RN 621685-45-8 HCAPLUS

CN Methanone, [5-methyl-4-[(2-methyl-5-propylphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-6-yl]phenyl- (9CI) (CA INDEX NAME)



RN 621685-46-9 HCAPLUS

CN Methanone, [5-methyl-4-[[2-methyl-5-(1-methylethyl)phenyl]amino]pyrrolo[2,1-f][1,2,4]triazin-6-yl]phenyl- (9CI) (CA INDEX NAME)



IT 621685-60-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of aryl ketone pyrrolotriazine compds. as



## p38 kinase inhibitors)

RN 621685-60-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(5-carboxy-2-methylphenyl)amino]-5-methyl-, 6-ethyl ester (9CI) (CA INDEX NAME)



IT 165245-96-5, p38 Kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of aryl ketone pyrrolotriazine compds. as p38 kinase inhibitors)

RN 165245-96-5 HCAPLUS

CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:875173 HCAPLUS

DOCUMENT NUMBER: 139:381511

TITLE: Pyrrolotriazine aniline compounds useful as kinase inhibitors, particularly p38 kinases, and their preparation, pharmaceutical compositions, and use as antiinflammatory agents

INVENTOR(S): Dyckman, Alaric; Hynes, John; Leftheris, Katherina; Liu, Chunjian; Wroblewski, Stephen T.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090912	A1	20031106	WO 2003-US12426	20030415
WO 2003090912	C2	20040108		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2483164 AA 20031106 CA 2003-2483164 20030415  
 EP 1497019 A1 20050119 EP 2003-724157 20030415  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003009669 A 20050301 BR 2003-9669 20030415  
 JP 2005523338 T2 20050804 JP 2003-587532 20030415  
 NO 2004004560 A 20041110 NO 2004-4560 20041022  
 PRIORITY APPLN. INFO.: US 2002-374938P P 20020423  
 WO 2003-US12426 W 20030415  
 OTHER SOURCE(S): MARPAT 139:381511  
 GI



AB Title compds. I and their enantiomers, diastereomers, pharmaceutically acceptable salts, prodrugs, and solvates are useful as **p38** kinase inhibitors [wherein: A = certain substituted Ph rings, particularly bearing various carboxamide and sulfonamide substituents; X = O, OCO, S, S(O), SO<sub>2</sub>, CO, CO<sub>2</sub>, (un)substituted NH, NHCO, NHCONH, NHCO<sub>2</sub>, NHSO<sub>2</sub>, NHSO<sub>2</sub>NH, SO<sub>2</sub>NH, or CONH, halo, NO<sub>2</sub>, cyano, or bond; R1, R5 = H, (un)substituted alkyl, OH or derivs., SH or derivs., CO<sub>2</sub>H or derivs., NH<sub>2</sub> or derivs., halo, NO<sub>2</sub>, cyano; R2 = H, alkyl; R3 = H, Me, CF<sub>3</sub>, MeO, halo, cyano, NH<sub>2</sub>, or NHMe; R4 = H (with provisos), (un)substituted alk(en/yn)yl, (hetero)aryl, (hetero)cycloalkyl, or absent]. Over 300 specific compds. I and various intermediates were prepared. Compds. I selectively inhibited human **p38.alpha./beta** isoenzymes and TNF- $\alpha$  in vitro (no data). For instance, 3-amino-4-methylbenzoic acid was amidated quant. with cyclopropylamine using EDC and DMAP in DMF. The pyrrolotriazinone ester II was then chlorinated at the ring oxo group with POCl<sub>3</sub> (100%). Aminolysis of the resulting chloride with the benzamide product from the first step gave 80% invention compound III.

IT 427878-38-4P 427878-44-2P 427878-45-3P  
 623152-11-4P 623152-13-6P 623152-14-7P

623152-15-8P 623152-16-9P 623152-17-0P  
 623152-18-1P 623152-24-9P 623152-25-0P  
 623152-26-1P 623152-27-2P 623152-34-1P  
 623152-35-2P 623152-36-3P 623152-37-4P  
 623152-38-5P 623152-39-6P 623152-40-9P  
 623152-41-0P 623152-42-1P 623152-43-2P  
 623152-44-3P 623152-45-4P 623152-46-5P  
 623152-47-6P 623152-62-5P 623152-68-1P  
 623152-71-6P 623152-72-7P 623152-73-8P  
 623152-74-9P 623152-75-0P 623152-76-1P  
 623152-77-2P 623152-78-3P 623152-79-4P  
 623152-80-7P 623152-82-9P 623153-08-2P  
 623153-09-3P 623153-10-6P 623153-11-7P  
 623153-12-8P 623153-13-9P 623153-14-0P  
 623153-15-1P 623153-16-2P 623153-17-3P  
 623153-18-4P 623153-19-5P 623153-20-8P  
 623153-21-9P 623153-22-0P 623153-23-1P  
 623153-24-2P 623153-25-3P 623153-26-4P  
 623153-27-5P 623153-28-6P 623153-29-7P  
 623153-30-0P 623153-31-1P 623153-32-2P  
 623153-33-3P 623153-34-4P 623153-35-5P  
 623153-37-7P 623153-39-9P 623153-40-2P  
 623153-41-3P 623153-44-6P 623153-45-7P  
 623153-46-8P 623153-47-9P 623153-48-0P  
 623153-51-5P 623153-52-6P 623153-53-7P  
 623153-54-8P 623153-55-9P 623153-56-0P  
 623153-57-1P 623153-58-2P 623153-60-6P  
 623153-61-7P 623153-62-8P 623153-63-9P  
 623153-64-0P 623153-65-1P 623153-66-2P  
 623153-67-3P 623153-68-4P 623153-69-5P  
 623153-70-8P 623153-71-9P 623153-72-0P  
 623153-73-1P 623153-74-2P 623153-75-3P  
 623153-76-4P 623153-77-5P 623153-78-6P  
 623153-79-7P 623153-80-0P 623153-81-1P  
 623153-82-2P 623153-83-3P 623153-84-4P  
 623153-85-5P 623153-86-6P 623153-87-7P  
 623153-88-8P 623153-89-9P 623153-90-2P  
 623153-91-3P 623153-92-4P 623153-93-5P  
 623153-94-6P 623153-95-7P 623153-96-8P  
 623153-97-9P 623153-98-0P 623153-99-1P  
 623154-00-7P 623154-01-8P 623154-02-9P  
 623154-03-0P 623154-04-1P 623154-05-2P  
 623154-06-3P 623154-07-4P 623154-08-5P  
 623154-09-6P 623154-10-9P 623154-11-0P  
 623154-12-1P 623154-13-2P 623154-14-3P  
 623154-15-4P 623154-16-5P 623154-17-6P  
 623154-18-7P 623154-19-8P 623154-20-1P  
 623154-21-2P 623154-22-3P 623154-23-4P  
 623154-24-5P 623154-26-7P 623154-28-9P  
 623154-30-3P 623154-31-4P 623154-32-5P  
 623154-34-7P 623154-36-9P 623154-37-0P  
 623154-38-1P 623154-39-2P 623154-40-5P  
 623154-41-6P 623154-42-7P 623154-43-8P  
 623154-44-9P 623154-45-0P 623154-46-1P  
 623154-47-2P 623154-48-3P 623154-49-4P  
 623154-50-7P 623154-51-8P 623154-52-9P  
 623154-54-1P 623154-55-2P 623154-57-4P  
 623154-58-5P 623154-59-6P 623154-60-9P  
 623154-63-2P 623154-64-3P 623154-65-4P  
 623154-66-5P 623154-67-6P 623154-68-7P


623154-69-8P 623154-70-1P 623154-71-2P  
 623154-72-3P 623154-73-4P 623154-74-5P  
 623154-75-6P 623154-76-7P 623154-77-8P  
 623154-78-9P 623154-79-0P 623154-80-3P  
 623154-81-4P 623154-82-5P 623154-83-6P  
 623154-84-7P 623154-85-8P 623154-86-9P  
 623154-87-0P 623154-88-1P 623154-89-2P  
 623154-90-5P 623154-91-6P 623154-92-7P  
 623154-93-8P 623154-94-9P 623154-95-0P  
 623154-96-1P 623154-97-2P 623154-98-3P  
 623154-99-4P 623155-00-0P 623155-03-3P  
 623155-04-4P 623155-05-5P 623155-08-8P  
 623155-09-9P 623155-13-5P 623155-14-6P  
 623155-15-7P 623155-17-9P 623155-18-0P  
 623156-24-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolotriazine aniline compds. as p38 kinase inhibitors)

RN 427878-38-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-44-2 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427878-45-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623152-11-4 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 623152-13-6 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-butyl-4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 623152-14-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI)  
(CA INDEX NAME)



RN 623152-15-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 623152-16-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-


[(cyclopropylamino) carbonyl]-2-methylphenyl] amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623152-17-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino) carbonyl]-2-methylphenyl] amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623152-18-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino) carbonyl]-2-methylphenyl] amino]-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 623152-24-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 623152-25-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-(3-hydroxypropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 623152-26-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 623152-27-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-[(1R)-2-hydroxy-1-phenylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623152-34-1 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(1R,2R)-2-ethoxycyclopropyl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 623152-35-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(1R,2R)-2-ethoxycyclopropyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 623152-36-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(1R,2R)-2-ethoxycyclopropyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-phenylethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 623152-37-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(1R,2R)-2-hydroxycyclopropyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-phenylethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 623152-38-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]phenyl]amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 623152-39-6 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[[(1R,2S)-2-fluorocyclopropyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 623152-40-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-isoxazolylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623152-41-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(2-thiazolylamino)carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 623152-42-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[4-(1,1-dimethylethyl)-2-thiazolyl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623152-43-2 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[5-methyl-2-thiazolyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623152-44-3 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(3-isoxazolylamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)

NAME)




RN 623152-45-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(1,3,4-thiadiazol-2-ylamino)carbonyl]phenyl]amino] - (9CI) (CA INDEX NAME)




RN 623152-46-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(2-oxazolylamino)carbonyl]phenyl]amino] - (9CI) (CA INDEX NAME)




RN 623152-47-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(1H-pyrazol-3-ylamino)carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 623152-62-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-cyanoethyl)-4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 623152-68-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 623152-71-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 623152-72-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(1-methyl-2-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 623152-73-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 623152-74-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 623152-75-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 623152-76-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-




[(cyclopropylamino) carbonyl]-2-methylphenyl] amino]-N-(3-ethoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 623152-77-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino) carbonyl]-2-methylphenyl] amino]-N-[3-(dimethylamino)propyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 623152-78-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino) carbonyl]-2-methylphenyl] amino]-5-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 623152-79-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 623152-80-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-(2-hydroxypropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 623152-82-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-N-(2-methoxyethyl)-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 623153-08-2 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(4-morpholinyl)phenyl]amino]carbonyl]phenyl]amino] - (9CI) (CA INDEX NAME)



RN 623153-09-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[3-(4-morpholinyl)phenyl]amino]carbonyl]phenyl]amino] -N-[(1S)-1-phenylethyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-10-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(4-pyridinylamino)carbonyl]phenyl]amino] -N-[(1S)-1-phenylethyl] - (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 623153-11-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(2-pyridinylamino)carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-12-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 623153-13-9 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(1,3-dimethyl-1H-pyrazol-5-yl)amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI)  
(CA INDEX NAME)



RN 623153-14-0 HCAPLUS  
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 623153-15-1 HCAPLUS  
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[(1-phenyl-1H-pyrazol-5-yl)amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 623153-16-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]amino]carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 623153-17-3 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[[3-fluoro-5-(4-morpholinyl)phenyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-18-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-fluoro-5-(4-morpholinyl)phenyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-19-5 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(4-methyl-1-piperazinyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623153-20-8 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[[3-(4-methyl-1-piperazinyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-21-9 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(1H-pyrazol-1-yl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623153-22-0 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[[3-(1H-pyrazol-1-yl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 623153-23-1 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[[3-(1H-imidazol-1-yl)phenyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI)  
 (CA INDEX NAME)




RN 623153-24-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1H-imidazol-1-yl)phenyl]amino]carbonyl]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-25-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(2-oxo-1-pyrrolidinyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI)  
 (CA INDEX NAME)



RN 623153-26-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[[3-(2-oxo-1-pyrrolidinyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-27-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[2-(4-morpholinyl)-4-pyridinyl]carbonyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 623153-28-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[2-


(4-morpholinyl)-4-pyridinyl]carbonyl]amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-29-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[2-(4-morpholinyl)-4-pyridinyl]carbonyl]amino]phenyl]amino]-N-[1-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 623153-30-0 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 623153-31-1 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 623153-32-2 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino]-N-[1-(2-pyridinyl)ethyl]- (9CI)  
(CA INDEX NAME)



RN 623153-33-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-methoxyethyl)-5-methyl-4-


[[2-methyl-5-[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino] - (9CI) (CA INDEX NAME)



RN 623153-34-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-35-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-37-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-N-(2-hydroxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-39-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 623153-40-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 623153-41-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[1-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 623153-44-6 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623153-45-7 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 623153-46-8 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-47-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 623153-48-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-




methyl- (9CI) (CA INDEX NAME)




RN 623153-51-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-52-6 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-N-(2-methoxy-1-methylethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-53-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-54-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[2-(1-piperidinylethyl)- (9CI) (CA INDEX NAME)



RN 623153-55-9 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[2-(4-morpholinylethyl)- (9CI) (CA INDEX NAME)



RN 623153-56-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(3-methylbenzoyl)amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-57-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-58-2 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-60-6 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-(2,3-dihydroxypropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 623153-61-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-fluorobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-62-8 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-ethynylbenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-63-9 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-methoxybenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-64-0 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-chlorobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-65-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 623153-66-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[3-(trifluoromethoxy)benzoyl]amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-67-3 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[4-methylbenzoyl]amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-68-4 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-69-5 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-methoxybenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-70-8 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(2,4-difluorobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-71-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(2,4-dimethoxybenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-72-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3,5-dichlorobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-73-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3,5-bis(trifluoromethyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 623153-74-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(2,6-dichlorobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-75-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(benzoylamino)-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-76-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(4-pyridinylcarbonyl)amino]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-77-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-(dimethylamino)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-78-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(acetylamino)-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-79-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[(2-methyl-1-oxopropyl)amino]phenyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-80-0 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(cyclopentylcarbonyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623153-81-1 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(benzoylamino)-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-82-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[(4-pyridinylcarbonyl)amino]phenyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-83-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(3,5-dimethyl-4-isoxazolyl)carbonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-84-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-85-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(1,3-benzodioxol-5-ylcarbonyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-86-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3,4-dimethoxybenzoyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-87-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[3-(trifluoromethoxy)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-88-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[(pyrazinylcarbonyl)amino]phenyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-89-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(1H-benzimidazol-5-ylcarbonyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-90-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(2,3-dihydro-5-benzofuranyl)carbonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-91-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-fluorobenzoyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-92-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(3,4-difluorobenzoyl)amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-93-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-4-(trifluoromethoxy)benzoyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-94-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-2-methoxy-1-methylethyl]-5-methyl-4-[[2-methyl-5-[[4-(methylsulfonyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623153-95-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluoro-4-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 623153-96-8 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)






RN 623153-97-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623153-98-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 623153-99-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(4-cyanobenzoyl)amino]-2-methylphenyl]amino]-N-(2-hydroxyethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 623154-00-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[3-(1H-pyrazol-1-yl)benzoyl]amino]phenyl]amino] - (9CI) (CA INDEX NAME)




RN 623154-01-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-methoxyethyl)-5-methyl-4-[[2-methyl-5-[[3-(1H-pyrazol-1-yl)benzoyl]amino]phenyl]amino] - (9CI) (CA INDEX NAME)




RN 623154-02-9 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[3-(4-methyl-1-piperazinyl)benzoyl]amino]phenyl]amino] - (9CI) (CA INDEX NAME)



RN 623154-03-0 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-methoxyethyl)-5-methyl-4-[[2-methyl-5-[[3-(4-methyl-1-piperazinyl)benzoyl]amino]phenyl]amino]-(9CI) (CA INDEX NAME)




RN 623154-04-1 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[3-(1H-imidazol-1-yl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-(9CI) (CA INDEX NAME)



RN 623154-05-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-(1H-imidazol-1-


Pryor 10\_696178

yl)benzoyl]amino]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methyl- (9CI)  
(CA INDEX NAME)




RN 623154-06-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[3-(2-oxo-1-pyrrolidinyl)benzoyl]amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 623154-07-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-methoxyethyl)-5-methyl-4-[[2-methyl-5-[[3-(2-oxo-1-pyrrolidinyl)benzoyl]amino]phenyl]amino]- (9CI)  
(CA INDEX NAME)




RN 623154-08-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[3-(1-piperazinyl)benzoyl]amino]phenyl]amino] - (9CI) (CA INDEX NAME)




RN 623154-09-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-methoxyethyl)-5-methyl-4-[[2-methyl-5-[[3-(1-piperazinyl)benzoyl]amino]phenyl]amino] - (9CI) (CA INDEX NAME)




RN 623154-10-9 HCAPLUS


CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-11-0 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(acetylamino)-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-12-1 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(acetylamino)-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623154-13-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(1-oxopropyl)amino]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 623154-14-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(1-oxopropyl)amino]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-15-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(ethoxycarbonyl)amino]-2-methylphenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 623154-16-5 HCAPLUS

CN Carbamic acid, [3-[[6-[[[(1S)-2-methoxy-1-methylethyl]amino]carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylphenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623154-17-6 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[[(1S)-1-methylpropyl]amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]aminophenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623154-18-7 HCAPLUS


CN Carbamic acid, [3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylphenyl]-, ethyl ester (9CI) (CA INDEX NAME)






RN 623154-19-8 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[[(1-methylethyl)amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-20-1 HCAPLUS

CN Carbamic acid, [3-[[6-[[[(2-hydroxyethyl)amino]carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylphenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-21-2 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 623154-22-3 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, propyl ester (9CI) (CA INDEX NAME)




RN 623154-23-4 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 623154-24-5 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, 2-fluoroethyl ester (9CI) (CA INDEX NAME)




RN 623154-26-7 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 623154-28-9 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)




RN 623154-30-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyacetyl)amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 623154-31-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyacetyl)amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-32-5 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623154-34-7 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 623154-36-9 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623154-37-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 623154-38-1 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-39-2 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623154-40-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 623154-41-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[2-methyl-5-[2-(methylamino)-2-oxoethyl]phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-42-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[2-(methylamino)-2-oxoethyl]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)






RN 623154-43-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[2-(methylamino)-2-oxoethyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 623154-44-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[1-(oxopropyl)amino]carbonyl]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 623154-45-0 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-46-1 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino) carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 623154-47-2 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino) carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 623154-48-3 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 623154-49-4 HCAPLUS

CN Carbamic acid, [3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylbenzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 623154-50-7 HCAPLUS

CN Carbamic acid, [3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylbenzoyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-51-8 HCAPLUS

CN Carbamic acid, [3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylbenzoyl]-, 1-methylethyl ester (9CI)  
(CA INDEX NAME)




RN 623154-52-9 HCAPLUS


CN Carbamic acid, [3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylbenzoyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 623154-54-1 HCAPLUS  
 CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(methylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623154-55-2 HCAPLUS  
 CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[(methylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 623154-57-4 HCAPLUS  
 CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[[(1-methylethyl)amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 623154-58-5 HCAPLUS

CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[[(1-methylethyl)amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-59-6 HCAPLUS


CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[[(1-methylethyl)amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 623154-60-9 HCAPLUS  
 CN Carbamic acid, [4-methyl-3-[[5-methyl-6-[[[(1-methylethyl)amino]carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]benzoyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 623154-63-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(cyclopropylamino)carbonyl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 623154-64-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(cyclopropylamino)carbonyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623154-65-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[(methylamino)carbonyl]amino]carbonyl]phenyl]amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 623154-66-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(acetylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)







RN 623154-67-6 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-  
 [(methoxycarbonyl)amino]carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl  
 ester (9CI) (CA INDEX NAME)



RN 623154-68-7 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(acetylamino)carbonyl]-  
 2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623154-69-8 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[2-  
 methyl-1-oxopropyl]amino]carbonyl]phenyl]amino]-N-propyl- (9CI) (CA INDEX  
 NAME)




RN 623154-70-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[[ (cyclopropylcarbonyl) amino] carbonyl] -2-methylphenyl] amino] -5-methyl-N-  
propyl- (9CI) (CA INDEX NAME)




RN 623154-71-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[[ (cyclopropylcarbonyl) amino] carbonyl] -2-methylphenyl] amino] -N-ethyl-5-  
methyl- (9CI) (CA INDEX NAME)




RN 623154-72-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[(1-oxopropyl)amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 623154-73-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[[(ethoxycarbonyl)amino]methyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-74-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[[(benzoylamino)methyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-75-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(acetylamino)methyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 623154-76-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyacetyl)amino]methyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-77-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[2-methyl-5-[[[(1-oxopropyl)amino]methyl]phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-78-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[[(4-cyanobenzoyl)amino]methyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-79-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(benzoylamino)methyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 623154-80-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(benzoylamino)methyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623154-81-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(benzoylamino)methyl]-2-methylphenyl]amino]-N-(2-hydroxyethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 623154-82-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-  
[[ (methoxyacetyl) amino] methyl]-2-methylphenyl] amino]-5-methyl- (9CI) (CA  
INDEX NAME)




RN 623154-83-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[[ (methoxyacetyl) amino] methyl]-2-methylphenyl] amino]-5-methyl-N-propyl-  
(9CI) (CA INDEX NAME)




RN 623154-84-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-hydroxyethyl)-4-[[5-  
[[ (methoxyacetyl) amino] methyl]-2-methylphenyl] amino]-5-methyl- (9CI) (CA  
INDEX NAME)




RN 623154-85-8 HCAPLUS

Pyrrrol[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[(1-oxopropyl)amino]methyl]phenyl]amino]-	(9CI)	(CA INDEX NAME)
--	-------	-----------------



RN 623154-86-9 HCAPLUS


Pyrrrolo [2,1-f] [1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[(1-oxopropyl) amino] methyl] phenyl] amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 623154-87-0 HCAPLUS




CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-hydroxyethyl)-5-methyl-4-  
[[2-methyl-5-[[[(1-oxopropyl)amino]methyl]phenyl]amino]- (9CI) (CA INDEX  
NAME)




RN 623154-88-1 HCAPLUS

CN Carbamic acid, [[3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-  
f][1,2,4]triazin-4-yl]amino]-4-methylphenyl]methyl]-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 623154-89-2 HCAPLUS


CN Carbamic acid, [[4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,  
1-f][1,2,4]triazin-4-yl]amino]phenyl]methyl]-, ethyl ester (9CI) (CA  
INDEX NAME)



RN 623154-90-5 HCAPLUS  
 CN Benzoic acid, 3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methyl-, 2-formylhydrazide (9CI) (CA INDEX NAME)




RN 623154-91-6 HCAPLUS  
 CN Benzoic acid, 3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methyl-, 2-benzoylhydrazide (9CI) (CA INDEX NAME)




RN 623154-92-7 HCAPLUS

CN Hydrazinecarboxylic acid, 2-[3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methylbenzoyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-93-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[2-oxo-2-phenylethyl]amino]carbonyl]phenyl]amino]- (9CI) (CA INDEX NAME)




RN 623154-94-9 HCAPLUS

CN Benzoic acid, 3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methyl-, 2-acetylhydrazide (9CI) (CA INDEX NAME)




RN 623154-95-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(aminocarbonyl)-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623154-96-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(5-acetyl-2-methylphenyl)amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 623154-97-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-acetyl-2-methylphenyl)amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 623154-98-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-acetyl-2-methylphenyl)amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623154-99-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(fluoroacetyl)-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623155-00-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-(ethoxyacetyl)-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 623155-03-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[(1H-pyrrol-1-ylamino)carbonyl]phenyl]amino] - (9CI) (CA INDEX NAME)



RN 623155-04-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-N-(1-methylethyl)-4-[[2-methyl-5-[(1H-pyrrol-1-ylamino)carbonyl]phenyl]amino] - (9CI) (CA INDEX NAME)




RN 623155-05-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(1H-

pyrrol-1-ylamino)carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623155-08-8 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(2,5-dimethyl-1H-pyrrol-1-yl)amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623155-09-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(2,5-dimethyl-1H-pyrrol-1-yl)amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 623155-13-5 HCAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[[5-methyl-6-(1-oxo-2-butynyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino] - (9CI) (CA INDEX NAME)




RN 623155-14-6 HCAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[[5-methyl-6-(1-oxo-2-propynyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino] - (9CI) (CA INDEX NAME)




RN 623155-15-7 HCAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[[5-methyl-6-(1-oxobutyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino] - (9CI) (CA INDEX NAME)







RN 623155-17-9 HCAPLUS  
 CN Benzamide, 3-[(6-benzoyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-N-ethyl-4-methyl- (9CI) (CA INDEX NAME)



RN 623155-18-0 HCAPLUS  
 CN Benzamide, 3-[(6-benzoyl-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-4-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623156-24-1 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(2,5-dimethyl-1H-pyrrol-1-yl)amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)




IT 427878-34-0P 427878-56-6P 427878-58-8P  
 427878-59-9P 621685-60-7P 623155-23-7P  
 623155-39-5P 623155-41-9P 623155-43-1P  
 623155-45-3P 623155-46-4P 623155-47-5P  
 623155-58-8P 623155-61-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrrolo[2,1-f][1,2,4]triazine aniline compds. as p38 kinase inhibitors)


RN 427878-34-0 HCAPLUS

CN Benzoic acid, 3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methyl- (9CI) (CA INDEX NAME)




RN 427878-56-6 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 427878-58-8 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-59-9 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-amino-2-methylphenyl)amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 621685-60-7 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(5-carboxy-2-methylphenyl)amino]-5-methyl-, 6-ethyl ester (9CI) (CA INDEX NAME)




RN 623155-23-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-7-formyl-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623155-39-5 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[2-methyl-5-[[[2-(4-morpholinyl)-4-pyridinyl]carbonyl]amino]phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 623155-41-9 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[2-methyl-5-[[[3-(4-morpholinyl)benzoyl]amino]phenyl]amino]-, ethyl ester (9CI) (CA

INDEX NAME)



RN 623155-43-1 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[3-fluoro-5-(4-morpholinyl)benzoyl]amino]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 623155-45-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623155-46-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-amino-2-


methylphenyl)amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623155-47-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-(carboxymethyl)-2-methylphenyl]amino]-5-methyl-, 6-ethyl ester (9CI) (CA INDEX NAME)




RN 623155-58-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-(2-fluoro-1,1-dimethoxyethyl)-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 623155-61-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-(2-ethoxy-1-hydroxyethyl)-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



IT 165245-96-5, p38 Kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of pyrrolo[2,1-f][1,2,4]triazine aniline compds. as p38 kinase inhibitors)

RN 165245-96-5 HCAPLUS

CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


IT 427877-76-7 427878-02-2 623155-62-4

RL: RCT (Reactant); RACT (Reactant or reagent)  
(starting material; preparation of pyrrolo[2,1-f][1,2,4]triazine aniline compds. as p38 kinase inhibitors)

RN 427877-76-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427878-02-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 623155-62-4 HCAPLUS  
 CN Benzoic acid, 4-methyl-3-[[5-methyl-6-[(propylamino)carbonyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:391720 HCAPLUS

DOCUMENT NUMBER: 136:386144

TITLE: Preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivatives for use in treating p38 kinase-associated conditions

INVENTOR(S): Leftheris, Katerina; Barrish, Joel; Hynes, John; Wroblewski, Stephen T.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 108 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040486	A2	20020523	WO 2001-US49982	20011107
WO 2002040486	A3	20030912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,






CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,  
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
US, UZ, VN, YU, ZA, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,  
KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,  
IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG

CA 2429628	AA	20020523	CA 2001-2429628	20011107
AU 2002032760	A5	20020527	AU 2002-32760	20011107
EE 200300227	A	20031015	EE 2003-227	20011107
EP 1363910	A2	20031126	EP 2001-992298	20011107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004522713	T2	20040729	JP 2002-543494	20011107
NZ 525334	A	20050729	NZ 2001-525334	20011107
BR 2001015446	A	20050809	BR 2001-15446	20011107
BG 107750	A	20040130	BG 2003-107750	20030421
ZA 2003003786	A	20040816	ZA 2003-3786	20030515
NO 2003002229	A	20030716	NO 2003-2229	20030516

PRIORITY APPLN. INFO.:

US 2000-249877P	P	20001117
US 2001-310561P	P	20010807
WO 2001-US49982	W	20011107


OTHER SOURCE(S): MARPAT 136:386144  
GI



AB Title compds. I [R3 = H, Me, perfluoromethyl, MeO, halo, cyano, NH2; X = O, OC(O), S, S(O), SO2, C(O), CO2, amino, aminoacyl, etc. or X is absent;

Z = O, S, N, and CR20, wherein when Z = CR20 said carbon atom may form an (un)(un)substituted bicyclic aryl or heteroaryl with R4 and R5; R1 = H, CH3, OH, OCH3, SH, SCH3, acyloxy, etc.; R2 = H, alkyl, alkenyl, aryl, heteroaryl, etc.; R4 = (un)substituted aryl, heteroaryl, bicyclic 7-11 membered (un)saturated carbocyclic or heterocyclic ring; R5 = H, alkyl, etc. or alternatively, R4 and R5 taken together with Z form an (un)substituted bicyclic 7-11 membered aryl or heteroaryl; R6 = H, alkyl, aryl, heterocyclo, etc.; R20 = H, alkyl, etc. with some provisions] were prepared Over 150 compds. were disclosed. For instance, 1-Amino-3-methylpyrrole-2,4-dicarboxylic acid di-Me ester was prepared from the parent pyrrole (preparation given) and diphenylphosphorylhydroxylamine and reacted with formamide (165°C, 6 h) to give intermediate pyrrolo[2,1-f][1,2,4]triazine II in 90% yield. II was converted to the imino-chloride (POCl3) and treated with indoline to give example compound III. I are inhibitors of p38 kinase and are useful for the treatment of inflammatory disorders.

- IT 427878-02-2P, N-Ethyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug; preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivs. for use in treating p38 kinase-associated conditions)
- RN 427878-02-2 HCAPLUS
- CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



- IT 310442-50-3P, 4-[[3-[[Butylamino]sulfonyl]phenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester  
 310442-52-5P, 4-[[3-[[Acetylamino]phenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester 310442-57-0P,  
 4-[[1-Acetyl-2,3-dihydro-1H-indol-6-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester 310442-84-3P,  
 4-[[6-[[Acetylamino]-3-pyridinyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester 310443-13-1P,  
 4-[2,3-Dihydro-2-oxo-1H-indol-3-yl]-5-methoxypyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester 310443-27-7P, 4-[2,3-Dihydro-5-[[[2-hydroxyethyl]amino]sulfonyl]-2-oxo-1H-indol-3-yl]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester 310444-01-0P,  
 1,3-Dihydro-3-[5-methoxy-6-[[4-[4-methyl-1-piperazinyl]butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]-2H-indol-2-one 310444-03-2P,

1,3-Dihydro-3-[5-methoxy-6-[[4-[4-morpholinyl]butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]-2H-indol-2-one **310444-49-6P**,  
 2-Methyl-5-[[5-methyl-6-[3-[2H-1,2,3-triazol-2-yl]propoxy]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]phenol **427877-55-2P**  
**427877-58-5P**, 4-[[5-[[Ethylamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester  
**427877-67-6P**, N-[2,2-Dimethylpropyl]-N-methyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-68-7P**,  
 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[1-methylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
**427877-69-8P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-70-1P**, N-[2,2-Dimethylpropyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-71-2P**,  
 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
**427877-72-3P**, N-[1,1-Dimethylethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-73-4P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-N-[2-methoxyethyl]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-75-6P**,  
 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
**427877-76-7P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-80-3P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-[4-pyridinyl]ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-81-4P**,  
 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-[1-piperidinyl]ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
**427877-82-5P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-[4-morpholinyl]ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-87-0P**, N-[2-[4-Fluorophenyl]ethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-90-5P**,  
 N-[2-1H-Indol-3-ylethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-91-6P**, N-Butyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-93-8P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-methylbutyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-96-1P**,  
 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-phenoxyethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
**427877-98-3P**, N-Ethyl-N-methyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427877-99-4P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2,2,2-trifluoroethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-00-0P**,  
 N-[2-Fluoroethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
**427878-03-3P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2,2,3,3,3-pentafluoropropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-04-4P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(dimethylamino)ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
**427878-10-2P**, N-[(1S)-1-Cyano-2-phenylethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f]


f] [1,2,4]triazine-6-carboxylic acid amide **427878-17-9P**,  
4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
**427878-18-0P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-20-4P**, N-N-[1-[4-Fluorophenyl]ethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-27-1P**,  
4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-[[trifluoromethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester **427878-28-2P**, N-Ethyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5-[[trifluoromethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-29-3P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-N-propyl-5-[[trifluoromethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-30-6P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-methylpropyl]-5-[[trifluoromethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-31-7P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-phenylethyl]-5-[[trifluoromethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-32-8P 427878-33-9P**, N-Ethyl-5-methyl-4-[[2-methyl-5-[[[3-[[trifluoromethyl]phenyl]amino]carbonyl]phenyl]amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-35-1P**,  
4-[[5-[[[4-Cyanophenyl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-36-2P**, 5-Methyl-4-[[2-methyl-5-[[[phenylamino]carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-37-3P**,  
4-[[5-[[[4-Cyanophenyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-38-4P**, N-Ethyl-4-[[5-[[[3-fluorophenyl]sulfonyl]amino]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-44-2P**, 4-[[5-[[[3-Fluorophenyl]sulfonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-45-3P**,  
4-[[5-[[[3-Fluorophenyl]sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-46-4P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester **427878-47-5P**, N-Ethyl-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-48-6P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[(1S)-1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-49-7P**,  
4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[1-methylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-52-2P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-[4-morpholinyl]ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-53-3P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-[1-piperidinyl]ethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-54-4P**, N-[2-[Dimethylamino]ethyl]-4-[[5-[[methoxyamino]carbonyl]-2-methylphenyl]amino]-5,7-dimethylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-55-5P**,  
4-[[5-[[[Ethylamino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-60-2P**, 5-Methyl-4-[[2-methyl-5-[[[phenylamino]carbonyl]amino]phenyl]amino]-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-61-3P**,  
5-Methyl-4-[[2-methyl-5-[[[3-methylphenyl]amino]carbonyl]amino]phenyl]ami

no]-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
**427878-62-4P**, 4-[[5-[[[4-Cyanophenyl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-63-5P**, 4-[[5-[[[2,3-Dichlorophenyl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
**427878-64-6P**, 4-[[5-[[[4-Fluorophenyl]amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-65-7P**, 5-Methyl-4-[[2-methyl-5-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]amino]-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
**427878-66-8P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-67-9P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[1-phenylethyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide **427878-68-0P**, 4-[[5-[[Methoxyamino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[1-methylpropyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivs. for use in treating p38 kinase-associated conditions)


RN 310442-50-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-[(butylamino)sulfonyl]phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310442-52-5 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-(acetylamino)phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310442-57-0 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(1-acetyl-2,3-dihydro-1H-indol-6-yl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310442-84-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[6-(acetylamino)-3-pyridinyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310443-13-1 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 310443-27-7 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[2,3-dihydro-5-[[2-hydroxyethyl]amino]sulfonyl]-2-oxo-1H-indol-3-yl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310444-01-0 HCAPLUS  
 CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methoxy-6-[[4-(4-methyl-1-piperazinyl)butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)




RN 310444-03-2 HCAPLUS  
 CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methoxy-6-[[4-(4-morpholinyl)butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)




RN 310444-49-6 HCAPLUS

CN Phenol, 2-methyl-5-[[5-methyl-6-[3-(2H-1,2,3-triazol-2-yl)propoxy]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 427877-55-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(5-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(4-morpholinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 427877-58-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-




[(ethylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, methyl ester (9CI)  
(CA INDEX NAME)




RN 427877-67-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA INDEX NAME)




RN 427877-68-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 427877-69-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylpropyl)-(9CI) (CA INDEX NAME)




RN 427877-70-1 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-(9CI) (CA INDEX NAME)




RN 427877-71-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI)  
 (CA INDEX NAME)



RN 427877-72-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(1,1-dimethylethyl)-4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX  
 NAME)




RN 427877-73-4 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methyl-  
 (9CI) (CA INDEX NAME)



RN 427877-75-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427877-76-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427877-80-3 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-

pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 427877-81-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 427877-82-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 427877-87-0 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(4-fluorophenyl)ethyl]-4-  
 [[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA  
 INDEX NAME)



RN 427877-90-5 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(1H-indol-3-yl)ethyl]-4-  
 [[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA  
 INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 427877-91-6 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-butyl-4-[[5-  
 [(methoxyamino) carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX  
 NAME)



RN 427877-93-8 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-


Pryor 10\_696178

[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylbutyl)-  
(9CI) (CA INDEX NAME)



RN 427877-96-1 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenoxyethyl)-  
(9CI) (CA INDEX NAME)




RN 427877-98-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA  
INDEX NAME)






RN 427877-99-4 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 427878-00-0 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-fluoroethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 427878-03-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,3,3,3-pentafluoropropyl)- (9CI) (CA INDEX NAME)



RN 427878-04-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-10-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-1-cyano-2-phenylethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427878-17-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427878-18-0 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427878-20-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[1-(4-fluorophenyl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 427878-27-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-(trifluoromethyl)-, ethyl  
ester (9CI) (CA INDEX NAME)




RN 427878-28-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-(trifluoromethyl)- (9CI)  
(CA INDEX NAME)



RN 427878-29-3 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-propyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 427878-30-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-methylpropyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427878-31-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-phenylethyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427878-32-8 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-,  
 monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 427878-02-2  
 CMF C19 H22 N6 O3




CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 427878-33-9 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-  
 5-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino]- (9CI) (CA  
 INDEX NAME)




RN 427878-35-1 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[4-cyanophenyl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI)  
 (CA INDEX NAME)



RN 427878-36-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(phenylamino)carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427878-37-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[4-cyanophenyl]amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-


phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-38-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[[3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-44-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-methylethyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427878-45-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-




fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427878-46-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-47-5 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl- (9CI) (CA INDEX NAME)



RN 427878-48-6 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427878-49-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 427878-52-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-(4-  
morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 427878-53-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-(1-  
piperidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 427878-54-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-  
[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl- (9CI)  
(CA INDEX NAME)




RN 427878-55-5 HCAPLUS

CN	Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5- [[(ethylamino)carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)
----	--



RN 427878-60-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-  
[[ (phenylamino) carbonyl] amino] phenyl] amino] -N-propyl- (9CI) (CA INDEX  
NAME)




RN 427878-61-3 HCAPLUS

```


RN      427878-61-3      HCAPLOS
CN      Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[(3-
        methylphenyl)amino]carbonyl]amino]phenyl]amino]-N-propyl- (9CI) (CA INDEX
        NAME)

```




RN 427878-62-4 HCAPLUS

Pyrrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(4-cyanophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl-  
(9CI) (CA INDEX NAME)




RN 427878-63-5 HCAPLUS

Pyrrulo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[[5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 427878-64-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(4-fluorophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl-(9CI) (CA INDEX NAME)



RN 427878-65-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]amino]-N-propyl-(9CI) (CA INDEX NAME)



RN 427878-66-8 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-

[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenylethyl)-  
(9CI) (CA INDEX NAME)




RN 427878-67-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-phenylethyl)-  
(9CI) (CA INDEX NAME)




RN 427878-68-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylpropyl)-  
(9CI) (CA INDEX NAME)




IT 427877-66-5P 427878-34-0P 427878-42-0P  
 427878-56-6P, 5-Methyl-4-[[2-methyl-5-nitrophenyl]amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester 427878-58-8P, 5-Methyl-4-[[2-methyl-5-nitrophenyl]amino]-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide 427878-59-9P, 4-[[5-Amino-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid amide  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivs. for use in treating p38 kinase-associated conditions)  
 RN 427877-66-5 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 427878-34-0 HCAPLUS  
 CN Benzoic acid, 3-[[6-[(ethylamino)carbonyl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-4-methyl- (9CI) (CA INDEX NAME)







RN 427878-42-0 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-56-6 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 427878-58-8 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-59-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-amino-2-methylphenyl)amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



IT 165245-96-5, p38 Kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivs. for  
use in treating p38 kinase-associated conditions)


RN 165245-96-5 HCAPLUS

CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

=> => d stat que 117

L5 STR



```

VAR G1=CH/11
VAR G2=ME/14/17/X/CN/NH2
VAR G3=CH/19
VAR G4=CH3/OH/17/SH/23/26/N/X/CN
VAR G5=66/32/33/34
VAR G20=O/S/N/26/X/CN/AK/CY
NODE ATTRIBUTES:
NSPEC IS RC AT 34
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 33

```

```

STEREO ATTRIBUTES: NONE
L7      533 SEA FILE=REGISTRY SSS FUL L5
L8      350 SEA FILE=REGISTRY ABB=ON PLU=ON P38/BI
L9      128 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND KINASE
L10     47 SEA FILE=REGISTRY ABB=ON PLU=ON (MITOGEN(W)ACTIVATED OR
MAP)(L) KINASE(L) (P38 OR P(W)38)
L11     18 SEA FILE=HCAPLUS ABB=ON PLU=ON L7
L12     32869 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 OR L10 OR P38 OR P(W)38 OR
MAP(2A) KINASE OR MITOGEN(W)ACTIVATED
L13     5 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND L12
L14     13 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND (PAIN OR ?ACHE? OR
?EDEM? OR ?ANALGES? OR ?FEVER? OR ?IMMUNE? OR HIV? OR HTLV OR
?CANCER? OR ?NEOPLAS? OR ?MALIG? OR ?TUMOR? OR ?PROLIVER? OR
?ANGIOGEN? OR ?NEURODE? OR ?VIRAL? OR ?INFLAM? OR ?ASTHM? OR
?DIABET? OR (BLOOD OR BLD) (W) SUGAR OR BOWEL(W) DISEASE)
L15     8 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND (?PULMON? OR ?OSTEOPOR
? OR BONE(W) LOSS OR ?DEMENT? OR ?SENIL? OR ?ALZHEM? OR ?PSORI?
OR ?ARTHRI? OR ?GOUT?)
L16     4 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15)
L17     10 SEA FILE=HCAPLUS ABB=ON PLU=ON (L13 OR L14 OR L15) NOT L16

```

=>

=&gt;

=&gt; d ibib abs hitstr l17 1-10

L17 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:638632 HCAPLUS

DOCUMENT NUMBER: 143:133402

TITLE: Preparation of disubstituted pyrrolo[2,1-f][1,2,4]triazine derivatives as and antiproliferative agents

INVENTOR(S): Gavai, Ashvinikumar V.; Han, Wen-Ching; Chen, Ping; Ruediger, Edward H.; Mastalerz, Harold; Fink, Brian E.; Norris, Derek J.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065266	A2	20050721	WO 2004-US43282	20041223
WO 2005065266	A3	20051215		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,			SM
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005197339	A1	20050908	US 2004-19899	20041222
PRIORITY APPLN. INFO.:			US 2003-533361P	P 20031229
OTHER SOURCE(S):	MARPAT 143:133402			

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [R, R2 = independently (un)substituted hetero/aryl, heterocyclyl; R3, R4 = independently H, halo, (un)substituted alkyl, alkoxy, etc.; R5, R5a = H, halo, (un)substituted alkyl; X = O, NR5; Y = (C)n; N = 1-2; and their pharmaceutically acceptable salts, solvates, prodrugs and enantiomers] were prepared as inhibitors tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of **cancer** and other diseases. For example, a 7-step synthesis of II, starting from 4-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine, is given. Most preferred compds. I had IC50 values between 0.01 and 0.1  $\mu$ M in one or more HER1, HER2, and HER4 assays. I are useful for treating other diseases associated with signal transduction pathways operating through growth factor receptors.


IT 859205-94-0P, 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-5-

methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester  
**859205-96-2P**, (R)-3-[[[4-[[3-Chloro-4-(3-fluorobenzoyloxy)phenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamoyl]oxy]methyl]morpholine-4-carboxylic acid tert-butyl ester  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of disubstituted aminopyrrolotriazines as HER1, HER2 and HER4 inhibitors and antiproliferative agents)

RN 859205-94-0 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 859205-96-2 HCAPLUS

CN 4-Morpholinecarboxylic acid, 3-[[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]amino]carbonyl]oxy]methyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:567104 HCAPLUS

DOCUMENT NUMBER: 143:97400

TITLE: A preparation of (indazolylamino)pyrrolo[2,1-f][1,2,4]triazine derivatives, useful as antiproliferative agents

INVENTOR(S): Swaminathan, Shankar; Gavai, Ashvinikumar V.; Fan, Junying; Patel, Bharat P.; Norris, Derek J.; Corbett, Richard Michael; Zheng, Bin

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058245	A2	20050630	WO 2004-US41920	20041210
WO 2005058245	A3	20050804		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005209454	A1	20050922	US 2004-8719	20041209
PRIORITY APPLN. INFO.:			US 2003-529347P	P 20031212
			US 2004-8719	A 20041209
OTHER SOURCE(S):	MARPAT 143:97400			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to a preparation of (indazolylamino)pyrrolo[2,1-f][1,2,4]triazine derivs. of formula I [wherein: R is aryl or heterocyclyl; R1 is alkyl; R2 is heterocyclyl], useful as inhibitors of tyrosine kinase activity of growth factor receptors such as HER1, HER2, and HER4 (no biol. data). For instance, (indazolylamino)pyrrolo[2,1-f][1,2,4]triazine derivative II was prepared via Curtius rearrangement from (indazolylamino)pyrrolo[2,1-f][1,2,4]triazinecarboxylic acid derivative III, tert-Bu (R)-3-(hydroxymethyl)morpholine-4-carboxylate in the presence of diphenylphosphoryl azide and subsequent hydrolysis (yields: Curtius rearrangement: 82%, hydrolysis - 77%).

IT 714971-12-7P 856667-79-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (indazolylamino)pyrrolo[2,1-f][1,2,4]triazine derivs. useful as antiproliferative agents)

RN 714971-12-7 HCAPLUS


CN 4-Morpholinecarboxylic acid, 3-[[[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]amino]carbonyloxy)methyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 856667-79-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:216796 HCAPLUS



DOCUMENT NUMBER: 142:316688

TITLE: Preparation of N-heterocycle derivatives as modulators of chemokine receptor activity

INVENTOR(S): Carter, Percy H.; Cherney, Robert J.; Batt, Douglas G.; Duncia, John V.; Gardner, Daniel S.; Ko, Soo S.; Srivastava, Anurag S.; Yang, Michael G.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 437 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021500	A1	20050310	WO 2004-US27196	20040820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005054627	A1	20050310	US 2004-923619	20040819
PRIORITY APPLN. INFO.:			US 2003-496947P	P 20030821
			US 2004-923619	A 20040819
OTHER SOURCE(S):		MARPAT 142:316688		
GI				



AB Title compds. I [Ring B = saturated or partially unsatd., (un)substituted cycloalkyl or heterocycle; X = O or S; Z = bond, NR8CO, NR8CS, NR8CONH, etc.; R1 = H, (un)substituted-alkyl, -alkenyl, -aryl, etc.; R2 = (un)substituted aryl or heterocycle; R8 = H, alkyl, cycloalkyl; R10 = H or (un)substituted alkyl; R11 = H, alkyl, etc.; R12 = H, alkyl, (un)substituted carbocycle; R13 = H or (un)substituted alkyl; m = 0-1; p = 0-1; n = 0-3 with provision when n = 2 the two C atoms may join through a double bond], or pharmaceutically acceptable salt forms thereof, are prepared and disclosed as modulators of MCP-1. Thus, e.g., II was prepared from benzyl (3S)-2-oxo-1-(4-oxocyclohexyl)-pyrrolidin-3-ylcarbamate



(preparation given) via a reductive amination process followed by a substitution reaction with 4-chloro-6-(trifluoromethyl)quinazoline (preparation given). I were determined to be active (IC50 of 30  $\mu$ M or less)

in

the antagonism of MCP-1 binding to human peripheral blood mononuclear cells. As modulators of MCP-1, I should be useful in the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

IT 847998-74-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-heterocyclic derivs. with chemokine receptor activity)

RN 847998-74-7 HCAPLUS

CN 2-Pyrrolidinone, 1-[trans-4-[(1,1-dimethylethyl)amino]cyclohexyl]-3-[[6-(1,1-dimethylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:701975 HCAPLUS

DOCUMENT NUMBER: 141:225304

TITLE: Preparation of cyclohexyl-substituted lactams as cytokine receptor modulating agents

INVENTOR(S): Cherney, Robert J.; Carter, Percy; Duncia, John V.; Gardner, Daniel S.; Santella, Joseph B.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 385 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071460	A2	20040826	WO 2004-US4418	20040211
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,			

GQ, GW, ML, MR, NE, SN, TD, TG  
 US 2004186140 A1 20040923 US 2004-776828 20040211  
 EP 1606255 A2 20051221 EP 2004-710294 20040211  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 PRIORITY APPLN. INFO.: US 2003-446850P P 20030212  
 WO 2004-US4418 W 20040211  
 OTHER SOURCE(S): MARPAT 141:225304  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Cyclohexyl-substituted lactams I [A = (un)substituted saturated or partially saturated cycloalkyl or heterocycloalkyl group with 3-8 atoms; E = S(:O)pCHR3, CHR3NR3, C(:O)NR3, N(R3)C(:O)NR3, SO2N(R3), N(R3)SO2N(R3); G = (CHR10)n; J = CH2CH2, CH:CH un(substituted) with (R13)s; R1, R2 = (un)substituted aryl or heteroaryl ring; R3 = H, alkyl; R10 = H, (un)substituted alkyl (two R10 groups may together comprise a carbonyl group); R11, R12 (independently) = H, (un)substituted alkyl, aralkyl, heteroaralkyl,  $\epsilon$ -hydroxyalkyl,  $\epsilon$ -mercaptoalkyl,  $\epsilon$ -alkoxyalkyl, etc.; R13 = H, (un)substituted alkyl; X = O, S; Z = bond, (un)substituted aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminosulfonyl, aminosulfonylamino, carbonylamino, oxycarbonylamino, aminocarbonyloxy, alkenediyl, methylene, etc.; m = 0-1; n = 0-3; s = 0-1] such as II are prepared as modulators of cytokine activity for the treatment of diseases associated with cytokines and their receptors such as **inflammation**, osteo- and rheumatoid **arthritis**, **autoimmune** diseases, **HIV** infection, **inflammatory bowel disease**, **asthma**, multiple sclerosis, and atherosclerosis. E.g., 1,4-cyclohexanedione mono(ethylene ketal) is lithiated and acylated with Et cyanoformate, reductively aminated with (S)- $\alpha$ -methylbenzylamine, subjected to reduction with lithium aluminum hydride followed by hydrogenolysis with palladium hydroxide and protection with Cbz anhydride to yield nonracemic III. E.g., III undergoes substitution at the primary carbon with 4-bromophenyl disulfide and tributylphosphine followed by oxidation with mCPBA, Stille methylation of the p-bromophenyl moiety, hydrogenolysis of the Cbz protecting group, acylation with N-Cbz-L-methionine, and S-methylation and cyclization with Me iodide and cesium carbonate to yield IV. E.g., IV undergoes acid-catalyzed deketalization, titanium-mediated Meerwein-Ponndorf-Verley reduction with isopropylamine (giving a mixture of both epimers at the amine center), N-methylation with formaldehyde and sodium triacetoxyborohydride, hydrogenolysis of the Cbz protecting group on the aminopyrrolidinone, and acylation with 3-trifluoromethylbenzoic acid and HATU to yield II. The compds. are modulators of chemokine receptor activity (no data). In addition, methods of halolactamization and dehalogenation and reagents appropriate for such transformations are claimed.

IT 746669-36-3P 746669-37-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of cyclohexyl-substituted lactams as modulators for cytokine receptor activity in the treatment of conditions such as **inflammation**, rheumatoid **arthritis**, **asthma**, multiple sclerosis, and atherosclerosis)

RN 746669-36-3 HCAPLUS

CN 2-Pyrrolidinone, 3-[[6-(1,1-dimethylethyl)pyrrolo[2,1-f][1,2,4]triazin-4-

yl]amino]-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-  
[(phenylsulfonyl)methyl]cyclohexyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 746669-37-4 HCAPLUS

CN 2-Pyrrolidinone, 1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-  
[(phenylsulfonyl)methyl]cyclohexyl]-3-[(6-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-  
ylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:654775 HCAPLUS

DOCUMENT NUMBER: 141:190807

TITLE: Process for preparing pyrrolotriazine kinase inhibitors

INVENTOR(S): Chen, Bang-Chi; Zhao, Rulin; Sundeen, Joseph Edward; Leftheris, Katerina; Hynes, John; Wroblewski, Stephen T.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 20 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004157846	A1	20040812	US 2004-773002	20040205
CA 2515218	AA	20040826	CA 2004-2515218	20040205
WO 2004072030	A2	20040826	WO 2004-US3223	20040205
WO 2004072030	A3	20041028		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1590335 A2 20051102 EP 2004-708546 20040205

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: US 2003-445224P P 20030205  
WO 2004-US3223 W 20040205

OTHER SOURCE(S): CASREACT 141:190807; MARPAT 141:190807

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB An improved process for the preparation of certain pyrrolotriazine compds. such as I [R1, R2 = H, alkyl; R3 = H, alkyl, halo, CN, etc.; R4-R6 = H, alkyl, aryl, heteroaryl; n = 0-3; R7, R8 = H, alkyl, alkenyl, cycloalkyl, aryl, etc.; or NR7R8 = (un)substituted heterocyclyl, heteroaryl] is disclosed. Thus, reacting II [R4, R5 as above] with HO2CC(O)CHXR6 [X = a leaving group; R6 = as above] followed by reacting the resulting pyrrolotriazine III with an alc., reacting the ester with a chlorinating agent, reacting IV [R = alkyl, aryl, heteroaryl; R4-R6 as above] with an aniline V [R1-R3 as above], and reacting VI with an amine NHR7R8 afforded the compound I. 59 Compds. I were prepared The compds. I exhibit utility as p38 kinase inhibitors (no biol. data given).

IT 165245-96-5, p38 Kinase  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (process for preparing pyrrolotriazine p38 kinase inhibitors)

RN 165245-96-5 HCAPLUS


CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 427877-67-6P 427877-68-7P 427877-69-8P  
427877-70-1P 427877-71-2P 427877-72-3P  
427877-73-4P 427877-75-6P 427877-76-7P  
427877-80-3P 427877-81-4P 427877-82-5P  
427877-87-0P 427877-90-5P 427877-91-6P  
427877-93-8P 427877-96-1P 427877-98-3P  
427877-99-4P 427878-00-0P 427878-02-2P  
427878-03-3P 427878-04-4P 427878-10-2P  
427878-17-9P 427878-18-0P 427878-20-4P  
427878-66-8P 738617-11-3P 738617-12-4P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(process for preparing pyrrolotriazine p38 kinase inhibitors)


RN 427877-67-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA INDEX NAME)




RN 427877-68-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 427877-69-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 427877-70-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 427877-71-2 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 427877-72-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(1,1-dimethylethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 427877-73-4 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-75-6 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427877-76-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427877-80-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 427877-81-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(1-




piperidinyl)ethyl] - (9CI) (CA INDEX NAME)



RN 427877-82-5 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-morpholinyl)ethyl] - (9CI) (CA INDEX NAME)



RN 427877-87-0 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(4-fluorophenyl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)

Pryor 10\_696178



RN 427877-90-5 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(1H-indol-3-yl)ethyl]-4-  
 [[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA  
 INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 427877-91-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-butyl-4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX  
NAME)




RN 427877-93-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylbutyl)-  
(9CI) (CA INDEX NAME)




RN 427877-96-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenoxyethyl)-  
(9CI) (CA INDEX NAME)




RN 427877-98-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA INDEX NAME)




RN 427877-99-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 427878-00-0 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-fluoroethyl)-4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX  
 NAME)



RN 427878-02-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX  
 NAME)




RN 427878-03-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,3,3,3-  
 pentafluoropropyl)- (9CI) (CA INDEX NAME)



RN 427878-04-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-10-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-1-cyano-2-phenylethyl]-4-[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427878-17-9 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-  
methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427878-18-0 HCAPLUS  
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-  
methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427878-20-4 HCAPLUS  
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[1-(4-fluorophenyl)ethyl]-4-  
[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA  
INDEX NAME)



RN 427878-66-8 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenylethyl)-(9CI) (CA INDEX NAME)



RN 738617-11-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-2,5-dimethyl-(9CI) (CA INDEX NAME)






RN 738617-12-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-2,5-dimethyl-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 738617-11-3


CMF C20 H24 N6 O3



CM 2

CRN 75-75-2

CMF C H4 O3 S



IT 427877-66-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(process for preparing pyrrolotriazine p38 kinase inhibitors)

RN 427877-66-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester  
 (9CI) (CA INDEX NAME)



L17 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:531311 HCAPLUS

DOCUMENT NUMBER: 141:89122

TITLE: Preparation of C-6 modified indazolyl pyrrolotriazines  
 as antiproliferative agents

INVENTOR(S): Vite, Gregory D.; Gavai, Ashvinikumar V.; Fink, Brian  
 E.; Mastalerz, Harold; Kadow, John F.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004054514	A2	20040701	WO 2003-US39542	20031212
WO 2004054514	A3	20041007		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2509650	AA	20040701	CA 2003-2509650	20031212
EP 1569937	A2	20050907	EP 2003-813396	20031212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003016755	A	20051025	BR 2003-16755	20031212
US 2004142931	A1	20040722	US 2003-736476	20031215

US 6916815	B2	20050712		
US 2005222153	A1	20051006	US 2005-143279	20050602
NO 2005002733	A	20050707	NO 2005-2733	20050607
PRIORITY APPLN. INFO.:			US 2002-433190P	P 20021213
			WO 2003-US39542	W 20031212
			US 2003-736476	A3 20031215
OTHER SOURCE(S):	MARPAT	141:89122		
GI				



I



II

AB The title compds. [I; R = (un)substituted aryl, heterocyclyl; R1 = (un)substituted alkyl; R2 = H, (un)substituted alkyl, cycloalkyl, aryl, etc.; X = a bond, O, S, (un)substituted NH, etc.] and their pharmaceutically acceptable salts which inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents, were prepared E.g., a multi-step synthesis of (3S)-II.HCl, starting from 5-nitroindazole, was given. Preferred compds. I exhibit IC50 of < 5  $\mu$ M in one or more of HER1, HER2 and HER4 assays. The compds. I are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors. The pharmaceutical composition comprising the compound

I is claimed.

IT 714971-01-4P 714971-02-5P 714971-05-8P  
714971-07-0P 714971-08-1P 714971-12-7P  
714971-23-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of C-6 modified indazolyl pyrrolotriazines as antiproliferative agents)

RN 714971-01-4 HCAPLUS


CN Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-

methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, 3-(methylsulfonyl)propyl ester  
(9CI) (CA INDEX NAME)



RN 714971-02-5 HCAPLUS


CN Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, 2-amino-2-methylpropyl ester  
(9CI) (CA INDEX NAME)




RN 714971-05-8 HCAPLUS

CN Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, 3-(4-hydroxy-1-piperidinyl)propyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 714971-07-0 HCAPLUS

CN Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, (2R)-2-aminopropyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 714971-08-1 HCAPLUS

CN Carbamic acid, [4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, (2S)-2-aminopropyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 714971-12-7 HCAPLUS

CN 4-Morpholinecarboxylic acid, 3-[[[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]amino]carbonyl]oxy]methyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714971-23-0 HCAPLUS


CN Acetamide, N-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]- (9CI) (CA INDEX NAME)

BR 2003012940	A	20050621	BR 2003-12940	20030718
JP 2005538989	T2	20051222	JP 2004-523256	20030718
NO 2005000072	A	20050203	NO 2005-72	20050106
US 2005124621	A1	20050609	US 2005-35248	20050113
PRIORITY APPLN. INFO.:			US 2002-397256P	P 20020719
			US 2003-447213P	P 20030213
			US 2003-623171	A1 20030718
			WO 2003-US22826	W 20030718
OTHER SOURCE(S):		MARPAT 140:124558		
GI				



AB The present invention provides pyrrolo[2,1-f][1,2,4]triazine compds. I (Z = O, S, N, OH, Cl; when Z = O or S, R4 is absent; when Z = OH or Cl, both R4 and R5 are absent; when Z = N, R4 = H; X,Y = O, OCO, S, SO, SO2, CO, CO2, halo, NO2, CN, etc., or X and Y are absent; R1 = H, Me, OH, OMe, SH, SMe, halo, NO2, CN, etc.; R2,R3 = H, (substituted)alkyl, (substituted)alkenyl, (substituted)alkynyl, (substituted)aryl, (substituted)heterocyclo, etc.; when X = halo, NO2, or CN, R2 is absent; when Y = halo, NO2, or CN, R3 is absent; R5 = (unsubstituted)indole; R6 = H, (substituted)alkyl, (substituted)aryl, (substituted)heterocyclo, halo, etc.), and pharmaceutically acceptable salts thereof. I compds. inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1 (no data), thereby making them useful as anti-cancer agents. I compds. are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors. Thus, many I (R1,R4,R6 absent; R3Y = Me; Z = O; R5 = 2-methyl-4-fluoro-1H-indol-5-yl; X = O; R2 = (substituted)alkyl, arylalkyl, etc.) were synthesized.

IT 649735-42-2P 649735-43-3P 649735-44-4P  
649735-45-5P 649735-46-6P 649735-47-7P  
649735-48-8P 649735-49-9P 649735-50-2P  
649735-51-3P 649735-52-4P 649735-53-5P  
649735-54-6P 649735-55-7P 649735-56-8P  
649735-57-9P 649735-58-0P 649735-59-1P  
649735-61-5P 649735-62-6P 649735-63-7P  
649735-64-8P 649735-65-9P 649735-67-1P  
649735-68-2P 649735-69-3P 649735-70-6P  
649735-71-7P 649735-72-8P 649735-73-9P  
649735-74-0P 649735-75-1P 649735-76-2P  
649735-77-3P 649735-78-4P 649735-79-5P  
649735-80-8P 649735-81-9P 649735-82-0P  
649735-83-1P 649735-86-4P 649735-87-5P  
649735-88-6P 649735-89-7P 649735-90-0P  
649735-91-1P 649735-92-2P 649735-93-3P  
649735-94-4P 649735-95-5P 649735-96-6P  
649735-97-7P 649735-98-8P 649735-99-9P  
649736-00-5P 649736-01-6P 649736-02-7P  
649736-03-8P 649736-04-9P 649736-05-0P



L17 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:80847 HCAPLUS

DOCUMENT NUMBER: 140:124558

TITLE: Pyrrolo[2,1-b]triazine inhibitors of kinases for use in treatment of diseases associated with growth factor receptor signal transduction

INVENTOR(S): Bhide, Rajeev; Cai, Zhen-wei; Qian, Ligang; Barbosa, Stephanie

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009784	A2	20040129	WO 2003-US22826	20030718
WO 2004009784	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492804	AA	20040129	CA 2003-2492804	20030718
US 2004063707	A1	20040401	US 2003-622593	20030718
US 6969717	B2	20051129		
US 2004072832	A1	20040415	US 2003-623171	20030718
US 6869952	B2	20050322		
EP 1534290	A2	20050601	EP 2003-765881	20030718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				




649736-06-1P 649736-07-2P 649736-08-3P  
 649736-09-4P 649736-10-7P 649736-11-8P  
 649736-12-9P 649736-13-0P 649736-14-1P  
 649736-16-3P 649736-17-4P 649736-18-5P  
 649736-20-9P 649736-22-1P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrrolotriazine inhibitors of kinases for use in treatment of diseases associated with growth factor receptor signal transduction)


RN 649735-42-2 HCAPLUS

CN Sulfamide, [3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)



RN 649735-43-3 HCAPLUS


CN Methanesulfonamide, N-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)



RN 649735-44-4 HCAPLUS


CN 1,2-Propanediol, 3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 649735-45-5 HCAPLUS  
 CN 1,2-Propanediol, 3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-46-6 HCAPLUS  
 CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649735-47-7 HCAPLUS  
 CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 649735-48-8 HCAPLUS

CN 2-Propanol, 1-[[4-[[4-fluoro-2-methyl-1H-indol-5-yl]oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649735-49-9 HCAPLUS


CN 2-Propanol, 1-[[4-[[4-fluoro-2-methyl-1H-indol-5-yl]oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 649735-50-2 HCAPLUS

CN Ethanol, 2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-(9CI) (CA INDEX NAME)



RN 649735-51-3 HCAPLUS


CN Methanesulfonamide, N-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]-(9CI) (CA INDEX NAME)



RN 649735-52-4 HCAPLUS

CN 2-Butanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-4-(methylsulfonyl)-, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649735-53-5 HCAPLUS


CN 2-Butanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-4-(methylsulfonyl)-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 649735-54-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 5-methyl-4-[(2-methyl-1H-indol-5-yl)oxy]-6-[3-(1-piperidiny)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-55-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-(4-piperidiny)ethoxy]- (9CI) (CA INDEX NAME)




RN 649735-56-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-

Pryor 10\_696178


methyl-6-[3-(4-pyridinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-57-9 HCAPLUS


CN 2-Butanamine, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-N,N-dimethyl-4-(methylsulfonyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 649735-58-0 HCAPLUS


CN 2-Propanamine, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 649735-59-1 HCAPLUS

CN 2-Propanamine, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)


NAME)



RN 649735-61-5 HCAPLUS

CN L-Alanine, N,N-dimethyl-, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649735-62-6 HCAPLUS

CN L-Leucine, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649735-63-7 HCAPLUS


CN L-Alanine, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 649735-64-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(methanesulfonyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-65-9 HCAPLUS


CN Methanesulfonamide, N-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]propyl]- (9CI) (CA INDEX NAME)




RN 649735-67-1 HCAPLUS




CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-(methylsulfonyl)- (9CI)  
(CA INDEX NAME)



RN 649735-68-2 HCAPLUS  
CN Sulfamide, N'-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-hydroxypropyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 649735-69-3 HCAPLUS  
CN 1H-Imidazole-1-ethanol, 2-ethyl-α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]- (9CI)  
(CA INDEX NAME)




RN 649735-70-6 HCAPLUS

CN 1H-Imidazole-1-ethanol,  $\alpha$ -[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 649735-71-7 HCAPLUS

CN 1H-Imidazole-1-ethanol,  $\alpha$ -[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 649735-72-8 HCAPLUS

CN 1H-1,2,4-Triazole-1-ethanol,  $\alpha$ -[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 649735-73-9 HCAPLUS


CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-(3-pyridinyloxy)- (9CI)  
(CA INDEX NAME)



RN 649735-74-0 HCAPLUS  
CN 2-Pyrrolidinone, 1-[3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)




RN 649735-75-1 HCAPLUS  
CN 1-Propanol, 3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 649735-76-2 HCAPLUS  
CN Pyrrolo[2,1-f][1,2,4]triazine, 6-(2-bromoethoxy)-4-[(4-fluoro-2-methyl-1H-

indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 649735-77-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 6-(3,3-dimethoxypropoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 649735-78-4 HCAPLUS

CN 2-Propanone, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 649735-79-5 HCAPLUS

CN Sulfamide, N'-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 649735-80-8 HCAPLUS

CN Sulfamide, [2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 649735-81-9 HCAPLUS

CN Formamide, N-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 649735-82-0 HCAPLUS

CN Phosphonic acid, [3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]propyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 649735-83-1 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(methyldisulfanyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649735-86-4 HCAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649735-87-5 HCAPLUS

CN 4H-1,2,4-Triazole-4-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649735-88-6 HCAPLUS

CN 1H-1,2,3-Triazole-1-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649735-89-7 HCAPLUS

CN 2H-1,2,3-Triazole-2-ethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649735-90-0 HCAPLUS

CN 4H-1,2,4-Triazole-4-ethanol,  $\alpha$ -[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, ( $\alpha$ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 649735-91-1 HCAPLUS

CN 1H-1,2,4-Triazole-1-ethanol,  $\alpha$ -[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, ( $\alpha$ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 649735-92-2 HCAPLUS

CN 1H-1,2,3-Triazole-1-ethanol,  $\alpha$ -[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649735-93-3 HCAPLUS


CN 2H-1,2,3-Triazole-2-ethanol,  $\alpha$ -[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 649735-94-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-(1H-indol-5-yloxy)-5-methyl-6-[3-(1-piperidinyl)propoxy]-(9CI) (CA INDEX NAME)




RN 649735-95-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-1H-indol-5-yl)oxy]-5-methyl-6-[3-(1-piperidinyl)propoxy]-(9CI) (CA INDEX NAME)




RN 649735-96-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(1-piperidinyl)propoxy]-(9CI) (CA INDEX NAME)




RN 649735-97-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(6-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 649735-98-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, N-1H-indol-5-yl-5-methyl-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 649735-99-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, 5-methyl-N-(2-methyl-1H-indol-5-yl)-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 649736-00-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, N-(2,3-dimethyl-1H-indol-5-yl)-5-methyl-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 649736-01-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 649736-02-7 HCAPLUS

CN 1-Propanamine, 3-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 649736-03-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-(4-methyl-5-thiazolyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 649736-04-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-(methylthio)ethoxy]- (9CI) (CA INDEX NAME)




RN 649736-05-0 HCAPLUS


CN Ethanamine, 2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 649736-06-1 HCAPLUS  
 CN 2-Pyrrolidinone, 1-[2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 649736-07-2 HCAPLUS  
 CN 2-Pentanone, 5-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 649736-08-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 649736-09-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(6-methyl-2-pyridinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649736-10-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine, 6-[3-(1,1-dioxido-4-thiomorpholinyl)propoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 649736-11-8 HCAPLUS


CN Carbamic acid, [(1R)-1-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]methyl]-3-(methylsulfonyl)propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 649736-12-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[2-(2-thienyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 649736-13-0 HCAPLUS


CN 2-Butanone, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 649736-14-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-[(2-methoxyethoxy)methoxy]-5-methyl- (9CI) (CA INDEX NAME)







RN 649736-16-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine, 6-(2-fluoroethoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)



RN 649736-17-4 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine, 6-[2-(1,1-dioxido-4-thiomorpholinyl)ethoxy]-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 649736-18-5 HCAPLUS  
 CN 2-Pentanol, 5-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 649736-20-9 HCAPLUS

CN Carbamic acid, [5-methyl-4-[(2-methyl-1H-indol-5-yl)oxy]pyrrolo[2,1-f][1,2,4]triazin-6-yl]-, 3-(1-piperidinyl)propyl ester (9CI) (CA INDEX NAME)



RN 649736-22-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-[3-(methylthio)propoxy]- (9CI) (CA INDEX NAME)



IT 649736-29-8P 649736-32-3P 649736-33-4P  
649736-37-8P 649736-40-3P 649736-41-4P  
649736-42-5P 649736-44-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(pyrrolotriazine inhibitors of kinases for use in treatment of diseases)

associated with growth factor receptor signal transduction)


RN 649736-29-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 649736-32-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 6-(3-bromopropoxy)-4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)




RN 649736-33-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 5-methyl-4-phenoxy-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 649736-37-8 HCAPLUS


CN 2-Propanone, 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 649736-40-3 HCAPLUS

CN L-Leucine, N-[(phenylmethoxy)carbonyl]-, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 649736-41-4 HCAPLUS


CN L-Alanine, N-[(phenylmethoxy)carbonyl]-, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 649736-42-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 5-methyl-6-[3-(methylsulfonyl)propoxy]-4-phenoxy- (9CI) (CA INDEX NAME)



RN 649736-44-7 HCAPLUS  
 CN Methanesulfonamide, N-[3-[(5-methyl-4-phenoxy)pyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




L17 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:80698 HCAPLUS  
 DOCUMENT NUMBER: 140:146173  
 TITLE: Preparation of pyrrolo[2,1-f][1,2,4]triazines as selective VEGFR-2 and FGFR-1 kinase inhibitors for treatment of proliferative diseases  
 INVENTOR(S): Bhide, Rajeev; Ruel, Rejean; Thibeault, Carl; L'heureux, Alexandre  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009601	A1	20040129	WO 2003-US22554	20030718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492665	AA	20040129	CA 2003-2492665	20030718

US 2004063707	A1	20040401	US 2003-622593	20030718
US 6969717	B2	20051129		
US 2004072832	A1	20040415	US 2003-623171	20030718
US 6869952	B2	20050322		
EP 1539763	A1	20050615	EP 2003-765754	20030718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005538990	T2	20051222	JP 2004-523591	20030718
US 2005124621	A1	20050609	US 2005-35248	20050113
NO 2005000417	A	20050217	NO 2005-417	20050125
PRIORITY APPLN. INFO.:			US 2002-397256P	P 20020719
			US 2003-447213P	P 20030213
			US 2003-623171	A1 20030718
			WO 2003-US22554	W 20030718

OTHER SOURCE(S): MARPAT 140:146173  
GI



AB Title compds. I [Z = O, S, N, etc.; X, Y = O, OCO, S, etc.; R1 = H, CH3, OH, etc.; R2, R3 = H, (un)substituted alkyl, alkenyl etc.; R4 = (un)substituted 7-azaindolyl, e.g., F, Cl, Me; R5 = H, absent when Z = O, S; R6 = H, (un)substituted alkyl, aryl, etc.] and their pharmaceutically acceptable salts were prepared. For example, electrophilic substitution of compound I [R1 = H; R2X = benzyloxy; R3Y = CH3; ZR5R6 = Cl] with 4-fluoro-5-hydroxy-7-azaindole, e.g., prepared from 4-chloro-1H-pyrrolo[2,3-b]pyridine in 6-steps, afforded compound I [R1 = H; R2X = benzyloxy; R3Y = CH3; ZR5R6 = 4-fluoro-7-azaindol-5-yloxy] in 80% yield. In VEGFR-2 and FGFR-1 kinase assays, 38-examples of compds. I exhibited IC50 values ranging from 0.001-10  $\mu$ M. Of note, pyrrolotriazines I exhibited selective VEGFR-2 and FGFR-1 kinase inhibition (no data provided). Compds. I are claimed useful for the treatment of **cancer, inflammation, autoimmune diseases.**

IT 651743-83-8P 651743-84-9P 651743-88-3P  
651743-89-4P 651743-90-7P 651743-91-8P  
651743-92-9P 651743-93-0P 651743-94-1P  
651743-95-2P 651743-96-3P 651743-97-4P  
651743-98-5P 651743-99-6P 651744-00-2P  
651744-01-3P 651744-02-4P 651744-04-6P  
651744-09-1P 651744-10-4P 651744-11-5P  
651744-19-3P 651744-52-4P 651744-53-5P  
651744-54-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolotriazines as selective VEGFR-2 and FGFR-1 kinase inhibitors for treatment of proliferative diseases)

RN 651743-83-8 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-(1H-

pyrrolo[2,3-b]pyridin-5-yloxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 651743-84-9 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 651743-88-3 HCAPLUS

CN 2-Propanol, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651743-89-4 HCAPLUS

CN 2-Propanol, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651743-90-7 HCAPLUS

CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651743-91-8 HCAPLUS

CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651743-92-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-



yl)oxy]-5-methyl-6-[(2R)-2-(phenylmethoxy)propoxy]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651743-93-0 HCAPLUS

CN 2-Propanol, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651743-94-1 HCAPLUS

CN 2-Propanol, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651743-95-2 HCAPLUS

CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2S)- (9CI) (CA INDEX NAME)


INDEX NAME)

Absolute stereochemistry.




RN 651743-96-3 HCAPLUS

CN Sulfamide, [2-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 651743-97-4 HCAPLUS


CN Methanesulfonamide, N-[2-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 651743-98-5 HCAPLUS

CN Methanesulfonamide, N-[2-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)


INDEX NAME)



RN 651743-99-6 HCAPLUS

CN 2-Propanamine, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651744-00-2 HCAPLUS

CN 2-Propanamine, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651744-01-3 HCAPLUS

CN Ethanamine, 2-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-


Pryor 10\_696178

methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]- (9CI) (CA INDEX NAME)



RN 651744-02-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 651744-04-6 HCAPLUS

CN 2-Propanol, 1-[[5-methyl-4-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651744-09-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, 6-[(2R)-2-aminopropoxy]-N-(4-fluoro-


1H-pyrrolo[2,3-b]pyridin-5-yl)-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 651744-10-4 HCAPLUS


CN Sulfamide, [2-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 651744-11-5 HCAPLUS

CN 2-Propanol, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651744-19-3 HCAPLUS

CN 2-Propanol, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-3-methoxy-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651744-52-4 HCAPLUS

CN 2-Propanamine, 1-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 651744-53-5 HCAPLUS

CN 2-Propanamine, 1-[[4-[(4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 651744-54-6 HCAPLUS

CN 2-Propanol, 1-[[5-methyl-4-[(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, dihydrochloride, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


IT 651744-50-2

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of pyrrolo[2,1-f][1,2,4]triazines as selective VEGFR-2 and FGFR-1 kinase inhibitors for treatment of proliferative diseases)

RN 651744-50-2 HCAPLUS

CN 2-Propanol, 1-[[5-methyl-4-(methylsulfonyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 651744-24-0P 651744-28-4P 651744-29-5P

651744-30-8P 651744-31-9P 651744-32-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolotriazines as selective VEGFR-2 and FGFR-1 kinase inhibitors for treatment of proliferative diseases)

RN 651744-24-0 HCAPLUS

CN 2-Propanol, 1-[[5-methyl-4-(methylthio)pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 651744-28-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 6-[(2R)-2-azidopropoxy]-5-methyl-4-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 651744-29-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 6-[(2R)-2-azidopropoxy]-4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 651744-30-8 HCAPLUS

CN Carbamic acid, [2-[[5-methyl-4-phenoxypyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 651744-31-9 HCAPLUS

CN Carbamic acid, [2-[[5-methyl-4-(methylthio)pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 651744-32-0 HCAPLUS

CN Carbamic acid, [2-[[4-[(4-fluoro-1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:80644 HCAPLUS

DOCUMENT NUMBER: 140:146018

TITLE: Process for preparation of indolyloxypyrrolotriazines and their use as drugs.

INVENTOR(S): Bhide, Rajeev; Fan, Junying; Parlanti, Luca; Barbosa, Stephanie; Qian, Ligang; Cai, Zhen-wei; Gibson, Francis S.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009542	A2	20040129	WO 2003-US22755	20030721
WO 2004009542	A3	20040513		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004077858	A1	20040422	US 2003-622280	20030718
US 6933386	B2	20050823		
CA 2492861	AA	20040129	CA 2003-2492861	20030721
EP 1554281	A2	20050720	EP 2003-765846	20030721
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003012648	A	20050802	BR 2003-12648	20030721
JP 2006502120	T2	20060119	JP 2004-523221	20030721
US 2005124621	A1	20050609	US 2005-35248	20050113
PRIORITY APPLN. INFO.:			US 2002-397256P	P 20020719
			US 2003-447213P	P 20030213
			US 2003-622280	A 20030718




L17 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2000:841986 HCAPLUS  
 DOCUMENT NUMBER: 134:17506  
 TITLE: Preparation of pyrrolotriazines as kinases inhibitors  
 for treating **inflammation, cancer,**  
 and proliferative diseases  
 INVENTOR(S): Hunt, John T.; Bhide, Rajeev S.; Borzilleri, Robert  
 M.; Qian, Ligang  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 130 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071129	A1	20001130	WO 2000-US13420	20000516
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2373990	AA	20001130	CA 2000-2373990	20000516
EP 1183033	A1	20020306	EP 2000-930761	20000516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010482	A	20020423	BR 2000-10482	20000516
JP 2003500359	T2	20030107	JP 2000-619433	20000516
NZ 516292	A	20040130	NZ 2000-516292	20000516
AU 770377	B2	20040219	AU 2000-48524	20000516
TR 200103352	T2	20050321	TR 2001-200103352	20000516
US 6982265	B1	20060103	US 2000-573829	20000518
NO 2001005650	A	20011120	NO 2001-5650	20011120
ZA 2001009577	A	20030220	ZA 2001-9577	20011120
US 2006004007	A1	20060105	US 2005-190412	20050727
PRIORITY APPLN. INFO.:			US 1999-135265P	P 19990521
			US 2000-193727P	P 20000331
			WO 2000-US13420	W 20000516
			US 2000-573829	A3 20000518

US 2003-623171  
WO 2003-US22755A1 20030718  
W 20030721OTHER SOURCE(S) :  
GI

MARPAT 140:146018



I



II

AB Title compds. [I; X, Y = O, O<sub>2</sub>C, S, SO, SO<sub>2</sub>, CO, CO<sub>2</sub>, NR<sub>10</sub>, NR<sub>11</sub>CO, NR<sub>12</sub>CONR<sub>13</sub>, NR<sub>14</sub>CO<sub>2</sub>, NR<sub>15</sub>SO<sub>2</sub>, NR<sub>16</sub>SO<sub>2</sub>NR<sub>17</sub>, SO<sub>2</sub>NR<sub>18</sub>, CONR<sub>19</sub>, halo, NO<sub>2</sub>, cyano, null; R<sub>1</sub>, R<sub>6</sub> = H; R<sub>2</sub>, R<sub>3</sub> = H, (substituted) alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heteroaryl, heterocycloalkyl; R<sub>7</sub>-R<sub>19</sub> = H, (substituted) alkyl, aryl, heteroaryl, heterocyclyl; R<sub>43</sub> = H, F, Cl, Me; n = 0-2; R<sub>44</sub> = H, Me; with provisos], were prepared in a 6-step procedure starting from pyrrolotriazinecarboxylates (II; R<sub>50</sub> = alkyl, aryl; X<sub>1</sub> = halo). Thus, Et 4-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate (preparation given) was stirred with NaOEt in EtOH at 0° for 1 h to give 98% Et 4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate. The latter was stirred with MeMgBr in THF/Et<sub>2</sub>O at 0° for 4 h to give 100% 2-(4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)propan-2-ol. This was stirred with H<sub>2</sub>O<sub>2</sub>/BF<sub>3</sub>·Et<sub>2</sub>O in CH<sub>2</sub>Cl<sub>2</sub> at -3° to -40° to give 76% 4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol. Benzylation of the latter with PhCH<sub>2</sub>Br/K<sub>2</sub>CO<sub>3</sub> in DMF gave 6-benzyloxy-4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazine. Reflux of this with 1N HCl in EtOH gave 6-benzyloxy-4-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine. This was added to a mixture prepared from 4-fluoro-2-methyl-1H-indol-5-ol and NaH in DMF at -20° followed by warming to room temperature to give 95% 6-benzyloxy-4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine. Stirring of the latter with ammonium formate and Pd/C in DMF at room temperature for 2 h gave 64% 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol.

IT 649736-29-8P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(process for preparation of indolyloxypyrrolotriazines and their use as drugs)

RN 649736-29-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)


OTHER SOURCE(S) : MARPAT 134:17506  
GI



AB Title compds. [I; X, Y independently = O, OCO, S, SO, SO<sub>2</sub>, CO, CO<sub>2</sub>, NH, NHCO, NHCONH, bond; Z = O, S, N, CH; R<sub>1</sub> = H, CH<sub>3</sub>, OH, OCH<sub>3</sub>, SH, SCH<sub>3</sub>, NH<sub>2</sub>, CO<sub>2</sub>H, NO<sub>2</sub>, CN, halo; R<sub>2</sub>, R<sub>3</sub> independently = H, alkyl, alkenyl, alkynyl, aryl, heterocyclo; R<sub>4</sub>, R<sub>5</sub> independently = H, alkyl, aryl, heterocyclo; R<sub>4</sub>-R<sub>5</sub> = monocyclic 5-7 membered cyclic ring, bicyclic 7-11 membered cyclic ring; R<sub>6</sub> = H, alkyl, aryl, heterocyclo, halo], enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, carriers, and solvates, which inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2 and produce **antiangiogenic** effect, are prepared Title compds. I are useful as anti-cancer agents, **antiinflammatories** and agents for the treatment of diseases associated with signal transduction pathways operating through growth factor receptors. Thus, the title compound II was prepared


IT 310443-09-5P 310443-13-1P 310443-35-7P  
310443-39-1P 310443-40-4P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyrrolotriazines as kinases inhibitors useful in treating **inflammation, cancer, and proliferative diseases**)

RN 310443-09-5 HCAPLUS  
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-bromo-2-fluorophenyl)amino]-5-methoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 310443-13-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 310443-35-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methoxy-N-[3-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 310443-39-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methoxyphenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-40-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(5-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



IT 310442-35-4P 310442-50-3P 310442-52-5P

310442-57-0P 310442-84-3P 310443-08-4P

310443-10-8P 310443-11-9P 310443-12-0P

310443-24-4P 310443-25-5P 310443-27-7P


310443-34-6P 310443-36-8P 310443-37-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolotriazines as kinases inhibitors useful in treating inflammation, cancer, and proliferative diseases)


RN 310442-35-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 310442-50-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-[(butylamino)sulfonyl]phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310442-52-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-(acetylamino)phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310442-57-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(1-acetyl-2,3-dihydro-1H-indol-6-yl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




5/10/10  
102/103  
1-3,6-9,11  
4-carboxy


Pryor 10\_696178




RN 310442-84-3 HCAPLUS  
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[6-(acetylamino)-3-pyridinyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310443-08-4 HCAPLUS  
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 310443-10-8 HCAPLUS  
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(4-bromo-2-fluorophenyl)amino]-5-methoxy-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 310443-11-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(4-bromo-2-fluorophenyl)amino]-5-methoxy-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 310443-12-0 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methoxy-4-[(6-methoxy-3-pyridinyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 310443-24-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[2,3-dihydro-5-[[[2-(4-morpholinyl)ethyl]amino]sulfonyl]-2-oxo-1H-indol-3-yl]-5-methyl-, methyl

ester (9CI) (CA INDEX NAME)




RN 310443-25-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[2,3-dihydro-2-oxo-5-[[[2-(1-pyrrolidinyl)ethyl]amino]sulfonyl]-1H-indol-3-yl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310443-27-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[2,3-dihydro-5-[[[2-(2-hydroxyethyl)amino]sulfonyl]-2-oxo-1H-indol-3-yl]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310443-34-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 310443-36-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methoxy-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-37-9 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methyl-6-[2-(1H-1,2,4-triazol-1-yl)ethoxy]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)




IT 310444-73-6P 310444-74-7P 310444-85-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrrolo[2,1-f][1,2,4]triazines as kinases inhibitors useful in treating inflammation, cancer, and proliferative diseases)

RN 310444-73-6 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methylphenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 310444-74-7 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-methanol, 4-[[3-[[1,1-dimethylethyl)dimethylsilyl]oxy]-4-methylphenyl]amino]-5-methyl- (9CI)  
 (CA INDEX NAME)



RN 310444-85-0 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine, 5-methyl-4-phenoxy-6-[2-(1H-1,2,4-triazol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)




IT 310443-59-5P 310443-60-8P 310443-61-9P  
 310443-62-0P 310443-63-1P 310443-70-0P  
 310443-71-1P 310443-72-2P 310443-73-3P  
 310443-76-6P 310443-77-7P 310443-78-8P  
 310443-79-9P 310443-80-2P 310443-81-3P  
 310443-82-4P 310443-83-5P 310443-88-0P  
 310443-93-7P 310443-94-8P 310443-98-2P

310444-00-9P 310444-01-0P 310444-03-2P  
 310444-05-4P 310444-08-7P 310444-17-8P  
 310444-18-9P 310444-20-3P 310444-21-4P  
 310444-24-7P 310444-25-8P 310444-26-9P  
 310444-29-2P 310444-30-5P 310444-33-8P  
 310444-37-2P 310444-39-4P 310444-41-8P  
 310444-49-6P 310444-61-2P 310444-62-3P  
 310444-63-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrrolotriazines as kinases inhibitors useful in treating inflammation, cancer, and proliferative diseases)


RN 310443-59-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-N,5-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 310443-60-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 310443-61-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 310443-62-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-N-[[[3-(dimethylamino)propyl]amino]carbonyl]-N-ethyl-5-methyl- (9CI)  
(CA INDEX NAME)




RN 310443-63-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 310443-70-0 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 310443-71-1 HCAPLUS  
 CN Urea, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-N'-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 310443-72-2 HCAPLUS  
 CN Urea, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-N'-(3-(4-morpholinyl)propyl)- (9CI) (CA INDEX NAME)




RN 310443-73-3 HCAPLUS  
 CN Urea, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-N'-(4-(4-morpholinyl)butyl)- (9CI) (CA INDEX NAME)






RN 310443-76-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 310443-77-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(1H-1,2,3-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 310443-78-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(2H-1,2,3-triazol-2-yl)propyl]- (9CI) (CA INDEX NAME)




RN 310443-79-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 310443-80-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(2-methyl-1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 310443-81-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[4-(4-morpholinyl)butyl]- (9CI) (CA INDEX NAME)




RN 310443-82-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-N,5-dimethyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 310443-83-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(6-fluoro-2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 310443-88-0 HCAPLUS

CN 4-Morpholinebutanamide, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]- (9CI) (CA INDEX NAME)




RN 310443-93-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(4-bromophenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 310443-94-8 HCAPLUS

CN Propanamide, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 310443-98-2 HCAPLUS

CN 4-Morpholinepropanesulfonamide, N-[4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]- (9CI) (CA INDEX NAME)




RN 310444-00-9 HCAPLUS

CN 4-Morpholinebutanamide, N-[4-[5-(aminosulfonyl)-2,3-dihydro-2-oxo-1H-indol-3-yl]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]- (9CI) (CA INDEX NAME)




RN 310444-01-0 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methoxy-6-[[4-(4-methyl-1-piperazinyl)butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)




RN 310444-03-2 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methoxy-6-[[4-(4-morpholinyl)butyl]amino]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)




RN 310444-05-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-ethyl-3-hydroxyphenyl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310444-08-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-hydroxy-4-(1-methylethyl)phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310444-17-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-butyl-3-hydroxyphenyl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310444-18-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(3-hydroxy-4-propylphenyl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310444-20-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 310444-21-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-(2,3-dihydro-2-oxo-1H-indol-3-yl)-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 310444-24-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(4-ethyl-3-hydroxyphenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 310444-25-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(4-bromo-3-hydroxyphenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)







RN 310444-26-9 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(2H-1,2,3-triazol-2-yl)propyl]- (9CI)  
 (CA INDEX NAME)



RN 310444-29-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 310444-30-5 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI)  
 (CA INDEX NAME)




RN 310444-33-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 310444-37-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 310444-39-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[4-(dimethylamino)butyl]-4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 310444-41-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(methylsulfonyl)propyl]- (9CI) (CA INDEX NAME)




RN 310444-49-6 HCAPLUS

CN Phenol, 2-methyl-5-[[5-methyl-6-[3-(2H-1,2,3-triazol-2-yl)propoxy]pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino]- (9CI) (CA INDEX NAME)




RN 310444-61-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, N-(3-bromophenyl)-5-methyl-6-[3-(2H-1,2,3-triazol-2-yl)propoxy]- (9CI) (CA INDEX NAME)




RN 310444-62-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, N-(4-bromo-2-fluorophenyl)-5-methyl-6-[3-(2H-1,2,3-triazol-2-yl)propoxy]- (9CI) (CA INDEX NAME)



RN 310444-63-4 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[5-methyl-6-[3-(2H-1,2,3-triazol-2-yl)propoxy]pyrrolo[2,1-f][1,2,4]triazin-4-yl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d stat que  
L5 STR



VAR G1=CH/11  
VAR G2=ME/14/17/X/CN/NH2  
VAR G3=CH/19  
VAR G4=CH3/OH/17/SH/23/26/N/X/CN  
VAR G5=66/32/33/34  
VAR G20=O/S/N/26/X/CN/AK/CY  
NODE ATTRIBUTES:  
NSPEC IS RC AT 34  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 33

STEREO ATTRIBUTES: NONE

L7 533 SEA FILE=REGISTRY SSS FUL L5  
L8 350 SEA FILE=REGISTRY ABB=ON PLU=ON P38/BI  
L9 128 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND KINASE  
L10 47 SEA FILE=REGISTRY ABB=ON PLU=ON (MITOGEN(W)ACTIVATED OR  
MAP) (L) KINASE (L) (P38 OR P(W)38)  
L11 18 SEA FILE=HCAPLUS ABB=ON PLU=ON L7  
L12 32869 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 OR L10 OR P38 OR P(W)38 OR  
MAP (2A) KINASE OR MITOGEN (W) ACTIVATED  
L13 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND L12  
L14 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND (PAIN OR ?ACHE? OR  
?EDEM? OR ?ANALGES? OR ?FEVER? OR ?IMMUNE? OR HIV? OR HTLV OR  
?CANCER? OR ?NEOPLAS? OR ?MALIG? OR ?TUMOR? OR ?PROLIVER? OR  
?ANGIOGEN? OR ?NEURODE? OR ?VIRAL? OR ?INFLAM? OR ?ASTHM? OR  
?DIABET? OR (BLOOD OR BLD) (W) SUGAR OR BOWEL (W) DISEASE)  
L15 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND (?PULMON? OR ?OSTEOPOR  
? OR BONE (W) LOSS OR ?DEMENT? OR ?SENIL? OR ?ALZHEM? OR ?PSORI?  
OR ?ARTHRI? OR ?GOUT?)  
L16 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15)  
L17 10 SEA FILE=HCAPLUS ABB=ON PLU=ON (L13 OR L14 OR L15) NOT L16

L18 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 NOT (L16 OR L17)

=&gt; d ibib abs hitstr l18 1-4

L18 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1350723 HCAPLUS

DOCUMENT NUMBER: 144:88323

TITLE: Processes for preparation of 5-methyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one derivatives as intermediates of pyrrolo[2,1-f][1,2,4]triazine protein tyrosine kinase inhibitors

INVENTOR(S): Crispino, Gerard; Barbosa, Stephanie; Fan, Junying; Cai, Zhen-Wei

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005288289	A1	20051229	US 2005-165875	20050624
US 2005288290	A1	20051229	US 2005-167043	20050624
US 2006004006	A1	20060105	US 2005-167049	20050624
WO 2006004636	A2	20060112	WO 2005-US22682	20050628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2006004833	A2	20060112	WO 2005-US23099	20050628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2006004884	A2	20060112	WO 2005-US23198	20050628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,				

ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,  
KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,  
KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2004-583459P

P 20040628

US 2004-612563P

P 20040923

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The present invention is directed to intermediates (I) (Ra, Rb = Me, Et, Pr), (II) (P = H, protecting group), and (III) (P = protecting group, L = leaving group) that are useful for preparing 6-hydroxy-5-methyl-4-phenoxy-pyrrolo[2,1-f][1,2,4]triazines (IV) (R2 = H, halogen, cyano, NO2, OR5, NR6R7, each (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, or heterocycloalkyl; R5, R6, R7 = H, alkyl, cycloalkyl, aryl, or heteroaryl; P = protecting group). Processes for preparing such intermediates involve, e.g. contacting the carbinols I with an acid in the presence of a peroxide to give II (P = H). Thus, 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid Et ester in THF was treated with methylmagnesium bromide in THF at <35°, kept at 25-45° until the reaction was complete, cooled to 0°, and quenched by adding aqueous NH4Cl solution to give, after workup, 6-(1-Hydroxy-1-methylethyl)-5-methyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one (V). A mixture of V, 50% aqueous H2O2 solution, and THF was treated with a precooled solution of methanesulfonic acid in H2O at -5° to -0.7° in an ice/acetone bath, stirred at -2° for 95 min, quenched by adding a cooled solution of H2O, NaHSO3, and 28% aqueous NH4OH solution over 40 min at 15-20°, and stirred at room temperature for 20 min to give, after workup, 75.9% II (P = H). A mixture of II (P = H), diisopropylethylamine, and THF was cooled to 0-10°, treated with pivaloyl chloride at <20°, and stirred until the reaction was complete to give, after workup, II (R = pivaloyl) which was heated with POCl3 and diisopropylethylamine in MeCN at 85-90° for 4 h to give, after workup and silica gel flash chromatog., 78% III (P = pivaloyl, L = Cl). III (P = pivaloyl, L = Cl) was stirred with 2-fluoro-4-nitrophenol and K2CO3 in DMF at room temperature for 24 h to give, after workup and silica gel flash chromatog., 4-(2-fluoro-4-nitrophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl pivalate which was converted into 1-[3-fluoro-4-[(6-methoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)oxy]phenyl]-3-(2-phenylacetyl)thiourea (VI) in 4 steps.

IT **872206-52-5P**, 4-(2-Fluoro-4-nitrophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl pivalate **872206-68-3P**, 4-(2-Fluoro-4-nitrophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl ethylcarbamate **872206-70-7P**, 4-(4-Amino-2-fluorophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl ethylcarbamate **872206-79-6P**, Ethyl 4-(2-fluoro-4-nitrophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate **872206-82-1P**, Ethyl 4-(4-amino-2-fluorophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; processes for preparation of 5-methyl-3H-pyrrolo[2,1-

Pryor 10\_696178

f] [1,2,4]triazin-4-one derivs. as intermediates of pyrrolo[2,1-f] [1,2,4]triazine protein tyrosine kinase inhibitors)


RN 872206-52-5 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 872206-68-3 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 872206-70-7 HCAPLUS


CN INDEX NAME NOT YET ASSIGNED



RN 872206-79-6 HCAPLUS




CN INDEX NAME NOT YET ASSIGNED



RN 872206-82-1 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




IT 872206-41-2P, N-[3-Fluoro-4-[(6-methoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)oxy]phenyl]-N'-(2-phenylacetyl)thiourea  
 872206-62-7P, 1-[3-Fluoro-4-[(6-methoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)oxy]phenyl]-3-[2-(4-fluorophenyl)acetyl]thiourea  
 872206-66-1P, 4-[2-Fluoro-4-[N'-(2-(4-fluorophenyl)acetyl)ureido]phenoxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl ethylcarbamate 872206-75-2P, 4-[2-Fluoro-4-[N'-(2-(4-fluorophenyl)acetyl)thioureido]phenoxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl ethylcarbamate 872206-77-4P, Ethyl 4-[2-fluoro-4-[N'-(2-(4-fluorophenyl)acetyl)thioureido]phenoxy]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 872206-84-3P  
 872206-88-7P, 4-[2-Fluoro-4-[N'-(2-(4-fluorophenyl)acetyl)thioureido]phenoxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl pivalate 872206-92-3P, 4-[2-Fluoro-4-[3-(2-phenylacetyl)thioureido]phenoxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl pivalate  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(processes for preparation of 5-methyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one derivs. as intermediates of pyrrolo[2,1-f][1,2,4]triazine protein tyrosine kinase inhibitors)


RN 872206-41-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 872206-62-7 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 872206-66-1 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 872206-75-2 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 872206-77-4 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 872206-84-3 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 2-A




RN 872206-88-7 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A



PAGE 2-A




RN 872206-92-3 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED




L18 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1024924 HCAPLUS  
 DOCUMENT NUMBER: 143:460081  
 TITLE: New dual inhibitors of EGFR and HER2 protein tyrosine kinases  
 AUTHOR(S): Fink, Brian E.; Vite, Gregory D.; Mastalerz, Harold; Kadow, John F.; Kim, Soong-Hoon; Leavitt, Kenneth J.; Du, Karen; Crews, Donald; Mitt, Toomas; Wong, Tai W.; Hunt, John T.; Vyas, Dolatrai M.; Tokarski, John S.  
 CORPORATE SOURCE: Departments of Oncology Chemistry, Discovery Biology, and Computer Aided Drug Design, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(21), 4774-4779  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB A novel series of dual EGFR and HER2 inhibitors based on the pyrrolo[2,1-f][1,2,4]triazine nucleus is described. A general route toward their synthesis, which enables functionalization at multiple sites, was developed. Biol. evaluation in enzymic and cell-based assays has identified a series of C(6) carbamates with potent biochem. and cellular activities.  
 IT 869067-04-9P 869067-05-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of pyrrolotriazines as dual inhibitors of EGFR and HER2 protein tyrosine kinases)  
 RN 869067-04-9 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)





RN 869067-05-0 HCAPLUS.  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[[1-(phenylmethyl)-1H-indazol-5-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:130304 HCAPLUS  
 DOCUMENT NUMBER: 142:392380  
 TITLE: Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors  
 AUTHOR(S): Borzilleri, Robert M.; Cai, Zhen-Wei; Ellis, Christopher; Fargnoli, Joseph; Fura, Aberra; Gerhardt, Tracy; Goyal, Bindu; Hunt, John T.; Mortillo, Steven; Qian, Ligang; Tokarski, John; Vyas, Viral; Wautlet, Barri; Zheng, Xioping; Bhide, Rajeev S.  
 CORPORATE SOURCE: Departments of Oncology Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(5), 1429-1433  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB A versatile synthesis of the suitably functionalized pyrrolo[2,1-f][1,2,4]triazine nucleus is described. SAR at the C-5 and C-6 positions of the 4-(3-hydroxy-4-methylphenylamino)pyrrolo[2,1-f][1,2,4]triazine template led to compds. with good in vitro potency against VEGFR-2 kinase. Glucuronidation of the phenol group is mitigated by incorporation of a

basic amino group on the C-6 side chain of the pyrrolotriazine nucleus.


IT 310443-70-0P 310444-05-4P 310444-08-7P  
310444-18-9P 310444-26-9P 310444-29-2P  
310444-37-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors)


RN 310443-70-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 310444-05-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(4-ethyl-3-hydroxyphenyl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310444-08-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[3-hydroxy-4-(1-methylethyl)phenyl]amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310444-18-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[(3-hydroxy-4-propylphenyl)amino]-5-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 310444-26-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(2H-1,2,3-triazol-2-yl)propyl]- (9CI) (CA INDEX NAME)




RN 310444-29-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-N-(3-methoxypropyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 310444-37-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(3-hydroxy-4-methylphenyl)amino]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




IT 649736-33-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors)

RN 649736-33-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine, 5-methyl-4-phenoxy-6-[3-(1-piperidinyl)propoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:777390 HCAPLUS

DOCUMENT NUMBER: 139:292275

TITLE: Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors

INVENTOR(S): Godfrey, Jollie Duaine; Hynes, John; Dyckman, Alaric J.; Leftheris, Katerina; Shi, Zhongping; Wroblewski, Stephen T.; Doubleday, Wendel William; Grosso, John A.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 36,293.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003186982	A1	20031002	US 2002-289010	20021106
US 6867300	B2	20050315		
US 2003069244	A1	20030410	US 2001-36293	20011107
US 6670357	B2	20031230		
ZA 2003003786	A	20040816	ZA 2003-3786	20030515
US 2004229877	A1	20041118	US 2003-696178	20031029
CA 2505365	AA	20040527	CA 2003-2505365	20031103
WO 2004043912	A2	20040527	WO 2003-US35220	20031103
WO 2004043912	A3	20040701		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1562949	A2	20050817	EP 2003-781756	20031103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016056	A	20050927	BR 2003-16056	20031103
US 2005107462	A1	20050519	US 2004-19788	20041222
PRIORITY APPLN. INFO.:			US 2000-249877P	P 20001117
			US 2001-310561P	P 20010807
			US 2001-36293	A2 20011107
			US 2002-289010	A 20021106
			WO 2003-US35220	W 20031103

OTHER SOURCE(S): MARPAT 139:292275

GI



AB Methods are claimed for the preparation kinase inhibiting pharmaceutical compds. I (R1 = H, alkyl, aralkyl, OR1', CO2R1', CO2(OR1'), CO2NR1'NR1'' and SO3NR1'R1'' (R1' and R1'' = H, alkyl, aryl, aralkyl, heterocyclo or cycloalkyl or R1' + R1'' = cycloalkyl, aryl, heterocyclic group); A = R1X or E where X = O, OC(O), S, SO, SO2, CO, CO2, substituted NHCO2, NHSO2, NHCONH, SO2NH or CONH, halo, NO2, CN, nul; E is electron withdrawing group; R1 + A = substituted (un)saturated aromatic or heterocyclic ring; R2 =

H, alkyl, alkenyl, alkynyl, (un)substituted aryl and heteroaryl, (un)substituted heterocyclo and cycloalkyl, (un)substituted carbonyl; R3 = H, OH, C1-6alkoxy, alkyl, C1-6perfluoroalkyl, OC1-6perfluoroalkyl, cycloalkyl, heterocyclo, aryl, aralkyl, acyl, carbalkoxy, carboxamido, CN, halo, (un)substituted amine, NO2, etc.; Z = O, S, N; R4 = substituted aryl; R5 = H, (un)substituted alkyl, etc.; R6 = H, (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclo, aralkyl, amino, alc., aryl, carbalkoxy, acyl, carboxamido) or a pharmaceutically acceptable salt or solvate. The methods according to the invention use an amination process, in which a pyrrole is reacted with a haloamine, preferably chloramine. This step is followed by cyclization to form the pyrrolo[2,1-f][1,2,4]triazine core. For example, N-cyclopropyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide was prepared by the amination of di-Et 3-methyl-1-pyrrole-2,4-dicarboxylate with chloramine followed by cyclization and addition of N-methoxy-3-amino-4-methylbenzamide hydrochloride, deprotection and reaction with cyclopropanamine.

IT 427877-66-5P 427878-02-2P 427878-42-0P


427878-56-6P 427878-58-8P 427878-59-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolo[2,1-f][1,2,4]triazine derivative as kinase inhibitor)


RN 427877-66-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 427878-02-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 427878-42-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[[[(3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 427878-56-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 427878-58-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[(2-methyl-5-nitrophenyl)amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 427878-59-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[(5-amino-2-methylphenyl)amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



IT 427877-67-6P 427877-68-7P 427877-69-8P  
427877-70-1P 427877-71-2P 427877-72-3P  
427877-73-4P 427877-75-6P 427877-76-7P




427877-80-3P 427877-81-4P 427877-82-5P  
 427877-87-0P 427877-90-5P 427877-91-6P  
 427877-93-8P 427877-96-1P 427877-98-3P  
 427877-99-4P 427878-00-0P 427878-03-3P  
 427878-04-4P 427878-10-2P 427878-17-9P  
 427878-18-0P 427878-20-4P 427878-27-1P  
 427878-28-2P 427878-29-3P 427878-30-6P  
 427878-31-7P 427878-33-9P 427878-35-1P  
 427878-36-2P 427878-37-3P 427878-38-4P  
 427878-44-2P 427878-45-3P 427878-46-4P  
 427878-47-5P 427878-48-6P 427878-49-7P  
 427878-52-2P 427878-53-3P 427878-54-4P  
 427878-55-5P 427878-60-2P 427878-61-3P  
 427878-62-4P 427878-63-5P 427878-64-6P  
 427878-65-7P 427878-66-8P 607738-96-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of pyrrolotriazine derivative as kinase inhibitor)


RN 427877-67-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-N,5-dimethyl- (9CI) (CA  
 INDEX NAME)




RN 427877-68-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(1-methylethyl)-  
 (9CI) (CA INDEX NAME)




RN 427877-69-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-methylpropyl)-(9CI) (CA INDEX NAME)




RN 427877-70-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2,2-dimethylpropyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 427877-71-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 427877-72-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(1,1-dimethylethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-73-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-(2-methoxyethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 427877-75-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427877-76-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427877-80-3 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 427877-81-4 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(1-  
 piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427877-82-5 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[2-(4-  
 morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 427877-87-0 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(4-fluorophenyl)ethyl]-4-  
 [[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA  
 INDEX NAME)



RN 427877-90-5 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(1H-indol-3-yl)ethyl]-4-  
 [[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA  
 INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 427877-91-6 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-butyl-4-[[5-  
 [(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX  
 NAME)



RN 427877-93-8 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-


Pryor 10\_696178

[(methoxyamino) carbonyl]-2-methylphenyl] amino]-5-methyl-N-(2-methylbutyl)-  
(9CI) (CA INDEX NAME)



RN 427877-96-1 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino) carbonyl]-2-methylphenyl] amino]-5-methyl-N-(2-phenoxyethyl)-  
(9CI) (CA INDEX NAME)



RN 427877-98-3 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-  
[(methoxyamino) carbonyl]-2-methylphenyl] amino]-N,5-dimethyl- (9CI) (CA  
INDEX NAME)






RN 427877-99-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 427878-00-0 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-(2-fluoroethyl)-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 427878-03-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2,2,3,3,3-pentafluoropropyl)- (9CI) (CA INDEX NAME)



RN 427878-04-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-10-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[(1S)-1-cyano-2-phenylethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427878-17-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427878-18-0 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427878-20-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[1-(4-fluorophenyl)ethyl]-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 427878-27-1 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 427878-28-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 427878-29-3 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-propyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 427878-30-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-methylpropyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427878-31-7 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-N-[(1S)-1-phenylethyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427878-33-9 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-5-methyl-4-[[2-methyl-5-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]amino] - (9CI) (CA INDEX NAME)



RN 427878-35-1 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[4-cyanophenyl]amino]carbonyl]-2-methylphenyl]amino]-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)



RN 427878-36-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[(phenylamino)carbonyl]phenyl]amino]-N-[(1S)-1-phenylethyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427878-37-3 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[4-cyanophenyl)amino]carbonyl]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-38-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-[[3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl- (9CI) (CA INDEX NAME)




RN 427878-44-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-N-[(1S)-2-methoxy-1-

methylethyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427878-45-3 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[3-fluorophenyl)sulfonyl]amino]-2-methylphenyl]amino]-5-methyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 427878-46-4 HCAPLUS


CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 427878-47-5 HCAPLUS




CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-ethyl-4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl- (9CI) (CA  
INDEX NAME)




RN 427878-48-6 HCAPLUS  
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[(1S)-1-  
phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 427878-49-7 HCAPLUS  
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-(1-  
methylethyl)- (9CI) (CA INDEX NAME)




RN 427878-52-2 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 427878-53-3 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 427878-54-4 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, N-[2-(dimethylamino)ethyl]-4-  
 [[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5,7-dimethyl- (9CI)  
 (CA INDEX NAME)




RN 427878-55-5 HCAPLUS  
 CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-  
 [(ethylamino)carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl-  
 (9CI) (CA INDEX NAME)




RN 427878-60-2 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-  
[[ (phenylamino) carbonyl] amino] phenyl] amino] -N-propyl- (9CI) (CA INDEX  
NAME)




RN 427878-61-3 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[(3-  
methylphenyl) amino] carbonyl] amino] phenyl] amino] -N-propyl- (9CI) (CA INDEX  
NAME)




RN 427878-62-4 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(4-cyanophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl-(9CI) (CA INDEX NAME)




RN 427878-63-5 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 427878-64-6 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[[[(4-fluorophenyl)amino]carbonyl]amino]-2-methylphenyl]amino]-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 427878-65-7 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 5-methyl-4-[[2-methyl-5-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]amino]-N-propyl- (9CI)  
(CA INDEX NAME)



RN 427878-66-8 HCAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 607738-96-5 HCAPLUS

CN Methanesulfonic acid, trifluoro-, compd. with N-ethyl-4-[[5-  
[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-  
f][1,2,4]triazine-6-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 427878-02-2


CMF C19 H22 N6 O3



CM 2

CRN 1493-13-6

CMF C H F3 O3 S



REFERENCE COUNT:

26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

**THIS PAGE BLANK (USPTO)**